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Worldwide, tuberculosis (TB) incidence increased from 
125 cases per 100,000 population in 1990 to 142 cases per 
100,000 population in 2004, primarily because of the human 
immunodeficiency virus (HIV) epidemic (1). Persons with 
HIV are at increased risk for TB disease, and those with TB 
have a high risk for death. This is documented most clearly in 
resource-limited settings, where limited access to antiretroviral 
therapy (ART) and other health-care services contribute to the 
elevated mortality (1). The impact of HIV on patients with TB 
is less clear in resource-rich nations such as the United States. 
To understand the impact of HIV on the risk for death during 
TB treatment in the United States, data were analyzed for all 
culture-positive patients with TB from 1993 to 2008, and the 
proportion that died was determined and stratified by HIV 
test result. Mortality data were restricted to patients reported 
before 2007. The proportion of all patients with TB who died 
during TB treatment decreased from 2,445 of 13,629 (18%) 
in 1993 to 682 of 7,578 (9%) in 2006. Among patients with 
TB and HIV, 950 of 2,337 (41%) died during treatment in 
1993; this proportion declined to 131 of 663 (20%) in 2006. 
The proportion of patients with TB and HIV who received 
their TB diagnosis postmortem dropped from 191 of 2,927 
(7%) in 1993 to 32 of 768 (4%) in 2006; 624 of 10,468 (6%) 
persons with TB and unknown HIV status received their TB 
Mortality Among Patients with 
Tuberculosis and Associations with HIV 
Status — United States, 1993–2008
World AIDS Day 2010
World AIDS Day (December 1) draws attention to 
the human immunodeficiency virus/acquired immunode-
ficiency syndrome (HIV/AIDS) epidemic worldwide. In 
the United States, approximately 56,000 persons become 
infected with HIV each year. The National HIV/AIDS 
Strategy calls for 1) educating all persons in the United States 
about the continued risk for HIV, 2) implementing inten-
sive, combined HIV-prevention programs in communities 
with high HIV prevalence, 3) ensuring access to services, 
and 4) reducing HIV-related health disparities (1).
Globally, at the beginning of 2003, approximately 
50,000 persons were receiving antiretroviral therapy (ART) 
in sub-Saharan Africa, where the need for such therapy 
was greatest (2). Currently, through the U.S. President’s 
Emergency Plan for AIDS Relief (PEPFAR) and a partner-
ship among many organizations, approximately 5 million 
persons receive ART in low-income and middle-income 
countries (3). Building on these successes, CDC focuses on 
strengthening systems and capacities of ministries of health 
to implement sustainable, evidence-based prevention, 
care, and treatment services. CDC also is working with its 
partners to ensure cost-effective programming and efficient 
implementation through increased technical assistance to 
multiple countries.
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diagnosis postmortem in 1993, and this proportion 
did not decline. Further reductions in mortality can be 
achieved by enhanced TB/HIV program collaboration 
and service integration. 
Since 1993, all cases of TB diagnosed in the United 
States have been reported to CDC and entered into 
the National TB Surveillance System (NTSS), a 
comprehensive database that contains demographic, 
clinical, and outcome data. All culture-confirmed 
cases of TB were reviewed by CDC to determine 1) 
the proportion of cases diagnosed postmortem and 
2) the proportion of cases in persons who were alive 
at diagnosis and who died during TB treatment; 
results then were stratified by HIV status (i.e., HIV 
infected, HIV uninfected, or HIV status unknown). 
The HIV-unknown category included patients with 
indeterminate or unknown results as well as patients 
who were not offered or refused testing. Rates of 
HIV test reporting during 2007–2008 were stratified 
by selected demographic characteristics. Mortality 
analyses were restricted to patients reported before 
2007 (to allow 2 years for treatment outcomes to 
be reported) and to those whose outcomes were 
known (excluding patients who moved, were lost 
to follow-up, were uncooperative with treatment, 
or whose outcome was missing or listed as other). 
Because California reports HIV test results only 
for patients who receive diagnoses of acquired 
immunodeficiency syndrome (AIDS), and does not 
report the HIV status of those who test negative, all 
data from California were excluded. 
The proportion of patients with TB who had docu-
mented HIV test results increased substantially, from 
6,015 of 16,507 (36%) in 1993 to 6,234 of 7,872 
(79%) in 2008 (Figure 1). The proportion of patients 
with TB who had a known outcome and were alive 
at diagnosis but died during TB treatment decreased 
from 2,445 of 13,629 (18%) in 1993 to 682 of 7,578 
(9%) in 2006 (Figure 2). Among patients with TB and 
HIV, 950 of 2,337 (41%) died during treatment in 
1993; this proportion declined to 299 of 1,393 (21%) 
in 1997 and later to 131 of 663 (20%) in 2006 (Figure 
2). By contrast, the proportion of TB patients with-
out HIV who died during treatment decreased from 
213 of 2,705 (8%) in 1993 to 281 of 5,315 (5%) in 
2006. For patients with unknown HIV status, 1,282 
of 8,587 (15%) died in 1993, with no decrease in 
proportion observed over the study period (Figure 2). 
Among patients with HIV who received diagnoses of 
TB, 191 of 2,927 (7%) received their TB diagnosis 
postmortem in 1993, which decreased to 32 of 768 
(4%) in 2006. Among culture-confirmed cases of TB 
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that occurred in persons who were HIV uninfected, 
53 of 3,080 (2%) received their TB diagnosis post-
mortem in 1993, a proportion that decreased to 31 
of 5,762 (1%) in 2006. Of those with unknown HIV 
status, 624 of 10,468 (6%) received their TB diagnosis 
postmortem; that proportion did not decline. 
Among those with known HIV status, 2,932 of 
6,015 (49%) patients with TB had HIV infection in 
1993 and accounted for 950 of 1,163 (82%) deaths 
during treatment and 191 of 244 (78%) patients who 
received a TB diagnosis postmortem. In 2006, 769 of 
6,533 (12%) patients with reported status had HIV, but 
accounted for 131 of 412 (32%) and 32 of 63 (51%) 
of those who died during treatment and those who 
received a TB diagnosis postmortem, respectively. 
HIV testing during 2007–2008 was lower in 
certain demographic groups than the overall sample, 
notably, 102 of 201 (51%) patients aged ≤4 years, 
95 of 144 (66%) patients aged 5–14 years, 1,824 of 
3,253 (56%) patients aged ≥65 years, and 2,154 of 
3,056 (70%) non-Hispanic white patients had HIV 
test results reported (Table). 
Reported by
S Shah, MD, Dept of Medicine, Albert Einstein College 
of Medicine, Bronx, New York. K Cain, MD, S Marks, 
MPH, MA, Div of TB Elimination, National Center for 
HIV/AIDS, Viral Hepatitis, STD, and TB Prevention; 
J Cavanaugh, MD, EIS Officer, CDC.
Editorial Note
This analysis demonstrates a substantial reduc-
tion in case-fatality rate among patients with TB in 
the United States from 1993 to 2006, a decline that 
occurred almost exclusively in persons with HIV 
and corresponded to an increase in reported HIV 
test results and broader availability of highly active 
ART. In 2008, however, 21% of patients with TB 
still had unknown HIV status, and this proportion 
was even higher in certain demographic groups. This 
is unacceptable given that knowledge of HIV status 
is essential for appropriate treatment and that current 
guidelines recommend HIV testing for all patients 
with TB in the United States (2). A larger propor-
tion of patients with TB were tested for HIV in some 
countries with a much higher burden of HIV and TB 
than the United States and far fewer resources, such 
as Kenya.* 
In resource-limited settings, studies have demon-
strated that without concurrent treatment of HIV, up 
to 50% of persons with HIV who develop TB will 
die during the 6- to 8-month course of TB treatment, 
many of them in the first 2 to 3 months (3,4). When 
patients with TB and HIV are treated with ART and 
prophylactic therapy for opportunistic infections as 
recommended (5), the proportion of patients who 
die during TB treatment can be reduced to less than 
10% (4). 
Recent research from New York City showed 
acceptable TB treatment success in patients with TB 
and HIV only when they received ART and directly 
observed therapy (6), underscoring the critical 
* Excludes California data because of lack of HIV data on patients with tuberculosis without 
AIDS.
FIGURE 1. Number of culture-confirmed tuberculosis patients with a recorded 






















* Excludes California data because of lack of HIV data on patients with tuberculosis without 
AIDS.
FIGURE 2. Case-fatality rates among culture-confirmed tuberculosis patients 
who were alive at diagnosis and whose treatment outcomes were known, by 




























Highly active antiretroviral therapy 
becomes widely available in the 
United States (1995–1996)
* Additional information available at http://www.nltp.co.ke/reports.
html.
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importance of these two treatment modalities. In this 
analysis, mortality declined steeply among patients 
with TB and HIV after highly active ART became 
widely available during 1995–1996. Data such as 
ART use, CD4 count, and specific cause of death are 
not reported to NTSS, and the impact of each of these 
could not be directly assessed; however, highly active 
ART use likely was an important factor in reducing 
mortality and, of course, can only be provided to those 
whose HIV infection is known. 
A substantial proportion of culture-confirmed TB 
diagnoses among persons with either documented 
HIV infection or unknown HIV status were made 
postmortem. Research has demonstrated that when 
patients with TB and HIV die from TB, it is often 
because diagnosis is delayed (7), and these deaths 
might have been prevented if TB disease had been 
diagnosed and treated earlier. Screening persons 
with HIV for TB at regular intervals in accordance 
with current recommendations (8) allows for earlier 
diagnosis and treatment of TB and has been shown 
to lower mortality (9).
TABLE. Number/sample and percentage of tuberculosis 
patients with a recorded HIV test result, by selected demo-
graphic characteristics — United States, 2007–2008
Characteristic No. (%)
Sex* 
Male  8,246/10,081 (82)
Female  4,568/6,019 (76)
Age group (yrs)†
 0–4  102/201 (51)
 5–14  95/144 (66)
 15–24  1,771/1,961 (90)
 25–44  4,938/5,543 (89)
 45–64  4,085/4,998 (82)
 ≥65  1,824/3,253 (56)
Race/Ethnicity§ 
Hispanic  3,591/4,254 (84)
American Indian/Alaska Native  168/215 (78)
Asian/Pacific Islander  2,571/3,533 (73)
Black, non-Hispanic  4,186/4,847 (86)
Native Hawaiian  72/95 (76)
White, non-Hispanic  2,154/3,056 (70)
Origin¶
Foreign-born  7,077/8,778 (81)
U.S.-born  5,713/7,275 (79)
* Two patients had missing data for sex; both were tested for HIV.
† Two patients had missing data for age; one was tested for HIV.
§ Forty-four patients were listed as multiple race/ethnicity; 36 (82%) 
were tested for HIV. Fifty-eight patients had missing data for race/
ethnicity; 38 (66%) were tested for HIV.
¶ Forty-nine patients had missing data for origin; 26 (53%) were 
tested for HIV.
Treatment of latent TB infection and use of ART 
have been shown to substantially reduce the risk for 
TB disease in persons with HIV (10). Increasing HIV 
testing of the general population will help identify 
those for whom early ART initiation and treatment 
of latent TB infection might prevent TB before it 
develops (10).
The findings in this report are subject to at 
least two limitations. First, California accounts for 
approximately 20% of the patients with TB in the 
United States, and excluding those data might affect 
generalizability if those patients differed from other 
patients with TB in key ways. Second, outcome data 
were missing for 10% of all patients included in this 
analysis, and NTSS does not document cause of death 
for those who died; knowledge of mortality concern-
ing these patients is limited.
Much progress has been made in reducing mortal-
ity among patients with TB and HIV in the United 
States since 1993. Further reductions in mortality 
can be achieved by enhanced TB and HIV program 
collaboration and service integration, including 
1) providing HIV testing to all patients with TB; 
2) screening all persons with HIV for TB disease 
and infection regularly; and 3) providing early and 
What is already known on this topic?
Data from resource-limited settings demonstrate a 
strong association between HIV infection and death 
among patients with TB; however, the effect of the 
HIV epidemic on patients with TB has not been well-
characterized in the United States.
What is added by this report?
The findings in this report show that mortality among 
patients with TB and HIV has decreased substantially 
in the United States since highly active antiretroviral 
therapy became widely available, and in conjunc-
tion with increased HIV testing of patients with TB; 
however, in 2006, nearly one quarter of patients with 
TB still had unknown HIV status, and nearly 20% of 
patients with TB and HIV died.
What are the implications for public health practice?
Mortality among patients with TB in the United States 
likely will be reduced by increasing the proportion of 
patients with TB tested for HIV, improving screening 
for TB among those known to be HIV infected, initiat-
ing early treatment for both diseases, and stepping up 
efforts to prevent TB. In addition, a better understand-
ing of causes of death would further improve practice.
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appropriate TB and HIV treatment to all patients with 
TB and HIV.† States and local health-care organiza-
tions should analyze their own data to determine how 
to best target interventions aimed at increasing HIV 
testing. In addition, studying the specific causes of 
death in patients with TB and HIV would facilitate 
development of additional measures to decrease the 
risk for death.
References 
 1. World Health Organization. Global tuberculosis control 
2010. Geneva, Switzerland: World Health Organization; 
2010. Available at http://www.who.int/tb/publications/
global_report/2010. Accessed on November 19, 2010. 
 2. CDC. Revised recommendations for HIV testing of adults, 
adolescents, and pregnant women in health-care settings. 
MMWR 2006;55(No. RR-14).
 3. Mukadi YD, Maher D, Harries A. Tuberculosis case fatality 
rates in high HIV prevalence populations in sub-Saharan 
Africa. AIDS 2001;15:143–52.
 4. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, 
Sungkanuparph S. Survival rate and risk factors of mortality 
among HIV/tuberculosis-coinfected patients with and 
without antiretroviral therapy. J Acquir Immune Defic Syndr 
2006;43:42–6.
 5. Sterling TR, Pham PA, Chaisson RE. HIV infection-related 
tuberculosis: clinical manifestations and treatment. Clin Infect 
Dis 2010;50(Suppl 3):S223–30.
 6. King L, Munsiff SS, Ahuja SD. Achieving international 
targets for tuberculosis treatments success among HIV-
positive patients in New York City. Int J Tuberc Lung Dis 
2010;14:1613–20.
 7. Cain KP, Anekthananon T, Burapat C. Causes of death in 
HIV-infected persons who have tuberculosis, Thailand. Emerg 
Infect Dis 2009;15:258–64.
 8. CDC. Guidelines for prevention and treatment of opportunistic 
infections in HIV-infected adults and adolescents: 
recommendations from CDC, the National Institutes of 
Health, and the HIV Medicine Association of the Infectious 
Diseases Society of America. MMWR 2009;58(No. RR-4).
 9. Reid A, Scano F, Getahun H. Towards universal access 
to HIV prevention, treatment, care, and support: the 
role of tuberculosis/HIV collaboration. Lancet Infect Dis 
2006;6:483–95.
 10. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent 
tuberculosis infection in HIV infected persons. Cochrane 
Database Syst Rev 2010;Jan 20:CD000171.
† Additional information available at http://www.who.int/hiv/pub/
tb/tbhiv/en/index.html.
MMWR  Morbidity and Mortality Weekly Report
1514 MMWR  /  November 26, 2010  /  Vol. 59  /  No. 46
In resource-limited settings, high case-fatality rates 
are seen among tuberculosis (TB) patients with human 
immunodeficiency virus (HIV) infection, especially 
during the early months of TB treatment (1). HIV 
prevalence among TB patients has been estimated to 
be as high as 80%–90% in some areas of sub-Saharan 
Africa (2). In 2004, the World Health Organization 
(WHO) recommended increasing collaboration 
between HIV and TB programs (3). Since then, many 
countries, including Kenya, have worked to increase 
TB/HIV collaborative activities. In 2005, the Kenya 
Division of Leprosy, Tuberculosis, and Lung Disease 
(DLTLD) added questions regarding HIV testing and 
treatment to the existing TB surveillance system.* This 
report summarizes HIV data collected from Kenya’s 
extended TB surveillance system during 2006–2009. 
During this period, HIV testing among TB patients 
increased from 60% in 2006 to 88% in 2009, and 
the prevalence of HIV infection among TB patients 
tested decreased from 52% to 44%. In 2009, 92% 
of HIV-infected TB patients received cotrimoxazole 
prophylaxis for the prevention of opportunistic infec-
tions (4). Although these data highlight the increase 
in HIV services provided to TB patients, only 34% 
of HIV-infected TB patients started antiretroviral 
therapy (ART) while being treated for TB. Innovative 
interventions are needed to increase HIV treatment 
among TB patients in Kenya, especially considering 
the 2009 WHO guidelines recommending that all 
HIV-infected TB patients be started on ART as soon 
as possible, regardless of CD4 count (5). Although 
these guidelines have not yet been implemented in 
Kenya, officials are working to identify methods of 
increasing access to ART for TB patients.
In 2004, the Kenya Ministry of Health (which 
in 2008 became the Ministry of Public Health and 
Sanitation [MOPHS]) established the TB/HIV 
Coordinating Committee to help develop policy and 
guidance for implementation of TB/HIV collabora-
tive activities. The committee recommended using 
the existing national TB program infrastructure to 
expand HIV counseling and testing services† to TB 
patients. In addition, the committee recommended 
using provider-initiated testing and counseling, an 
“opt-out” model in which HIV testing is performed 
routinely unless the patient declines. Because cot-
rimoxazole prophylaxis has been shown to reduce 
opportunistic infections and to decrease morbidity 
and mortality for HIV-infected TB patients, the 
committee recommended that TB clinics offer cotri-
moxazole prophylaxis to all HIV-infected TB patients 
(i.e., those with documentation of a positive HIV 
test result in the facility TB register) (6). Finally, the 
committee recommended that HIV-infected patients 
be referred to separate HIV care and treatment clinics 
for additional HIV care and evaluation for eligibility 
for ART.§
DLTLD is responsible for overseeing clinical 
activities at approximately 2,200 TB diagnostic 
and treatment facilities and for collecting routine 
surveillance data. Provincial and district TB/leprosy 
coordinators manage the network of TB facilities. 
District coordinators receive quarterly reports regard-
ing all patients with active TB disease who are newly 
registered (i.e., currently diagnosed with active TB 
disease and receiving TB treatment) at each TB clinic, 
compile this information into quarterly aggregate 
district reports, and then forward the reports to the 
provincial coordinators, who submit the information 
to DLTLD. 
In 2005, DLTLD added key HIV-related informa-
tion to the local TB facility register and the district-
level reporting forms: HIV testing status for TB 
patients, HIV test results, and receipt of cotrimoxazole 
prophylaxis, which are available directly from TB 
clinic records, and information about ART during 
HIV Testing and Treatment Among Tuberculosis Patients — 
Kenya, 2006–2009
* Available at http://www.nltp.co.ke/docs/annual_report_2007.pdf.
† HIV testing in Kenya follows an established algorithm that 
involves parallel or serial testing with two rapid HIV tests. If the 
two tests have discordant results, a third confirmatory test (rapid 
test or other confirmatory test) is used as a tie-breaker.  Rapid test 
results are provided to the patient on the same day that the test was 
conducted.
§ In Kenya, HIV-infected patients are eligible for ART if they have 
1) a CD4 count of <200 cells/mm3, 2) a CD4 count of 200–350 
cells/mm3 and WHO stage III disease, or 3) WHO stage IV disease 
(regardless of CD4 count).
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TB treatment, which generally is based on patient 
reports of care received at separate HIV clinics (8). 
By January 1, 2006, all TB districts in Kenya had 
added these HIV variables to the routine TB surveil-
lance reporting forms. For this report, data collected 
through the extended TB surveillance system during 
2006–2009 were analyzed.
From 2006 to 2009, the total number of newly 
registered TB patients reported each year decreased 
5%, from 115,234 to 110,015 (Table). The preva-
lence of HIV testing among TB patients increased 
from 60% (of 115,234 patients) to 88% (of 110,015 
patients), and the prevalence of HIV infection among 
TB patients tested decreased from 52% (of 69,337 
tested) in 2006 to 44% (of 96,280 tested) in 2009. 
In 2009, HIV prevalence among TB patients varied 
widely by province, ranging from 5% in North Eastern 
Province to 70% in Nyanza Province (Figure). 
Provision of cotrimoxazole prophylaxis to HIV-
infected TB patients remained high throughout this 
period; 87% received cotrimoxazole in 2006, and 
92% in 2009. During the same period, the percentage 
of HIV-infected TB patients receiving ART increased 
from 26% to 34% (Table). 
Reported by
J Sitienei, MD, H Kipruto, Kenya Div of Leprosy, 
Tuberculosis, and Lung Disease, Ministry of Public 
Health and Sanitation. L Nganga, MD, M Ackers, 
MD, J Odhiambo, MD, Global AIDS Program (Kenya). 
K Laserson, ScD, Center for Global Health, Kenya. 
AK Nakashima, MD, Global AIDS Program (Atlanta); 
S Modi, MD, EIS Officer, CDC. 
Editorial Note
Within 5 years of the addition of HIV activities 
to the country’s TB program, 88% of TB patients in 
Kenya were tested for HIV, and 92% of HIV-infected 
TB patients received cotrimoxazole prophylaxis in 
TB clinical settings. Elsewhere in sub-Saharan Africa, 
success with HIV testing of TB patients varies widely; 
Malawi tests approximately 80% of TB patients, 
but estimates of testing are lower in Uganda (60%), 
Zambia (60%), and South Africa (40%) (CDC, 
unpublished data, 2010).
HIV testing and clinical services in Kenya histori-
cally have been provided through the National AIDS 
and STI Control Programme. However, the findings 
in this report show that DLTLD has been successful 
in providing key HIV services within the existing TB 
program infrastructure. Multiple actions were critical 
to achieving this success, including establishment of 
the TB/HIV Coordinating Committee, which assisted 
with development of national guidelines for HIV test-
ing in 2004 and promoted provider-initiated testing 
and counseling in multiple health-care settings (7). 
Provider-initiated testing and counseling has been 
shown to increase the proportion of patients tested 
when compared with traditional “opt-in” models in 
TABLE. HIV testing and care and treatment services among newly registered TB patients* — Kenya, 2006–2009 
HIV testing/Services
2006 (N = 115,234) 2007 (N = 116,723) 2008 (N = 110,251) 2009 (N = 110,015)
No. (%) No. (%) No. (%) No. (%)
Tested for HIV 69,337 (60%) 91,841 (79%) 91,463 (83%) 96,280 (88%)
HIV infected 36,136 (52%) 43,954 (48%) 41,174 (45%) 42,210 (44%)
Receiving CTX prophylaxis 31,438 (87%) 37,800 (86%) 37,757 (92%) 38,989 (92%)
Receiving ART 9,395 (26%) 11,867 (27%) 12,426 (30%) 14,259 (34%)
Abbreviations: HIV = human immunodeficiency virus; TB = tuberculosis; CTX = cotrimoxazole; ART = antiretroviral therapy.
* All patients who are currently diagnosed with active TB disease and are receiving TB treatment.
What is already known on this topic? 
TB is the leading cause of mortality worldwide for 
persons living with HIV infection, and HIV prevalence 
among TB patients in sub-Saharan Africa is estimated 
to be as high as 80%–90%.
What is added by this report?
Data from Kenya indicate increases in HIV testing 
among TB patients from 60% in 2006 to 88% in 2009; 
cotrimoxazole prophylaxis for opportunistic infec-
tions was provided to 92% of HIV-infected TB patients 
in 2009, but only 34% received potentially life-saving 
therapy with antiretroviral drugs during TB treatment.
What are the implications for public health practice?
Efforts to reach HIV-infected TB patients through 
national TB programs can be successful, but TB/
HIV collaborative efforts must be strengthened to 
increase use of antiretroviral therapy among these 
patients.
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which patients must request HIV testing (2). As HIV 
testing among newly registered TB patients increased, 
the prevalence of HIV among TB patients decreased, 
indicating that providers might have targeted early 
testing efforts to patients at greater risk for HIV (8). 
Overall, HIV prevalence among newly registered 
TB patients remains high, particularly in Nyanza 
Province (70%).
In addition to strong commitment to TB/HIV 
collaborative activities at the national level in Kenya, 
local leaders have been recruited to form regional 
TB/HIV coordinating bodies to translate national 
policy into action. These regional bodies implemented 
continuing medical education modules to promote 
provider-initiated testing and counseling and cot-
rimoxazole prophylaxis for HIV-infected patients 
as standard interventions in all TB clinical settings. 
Financial support from international donors including 
the U.S. President’s Emergency Plan for AIDS Relief 
(PEPFAR), WHO, and the Global Fund to Fight 
Abbreviations: HIV = human immunodeficiency virus; TB = tuberculosis.
* All patients who are currently diagnosed with active TB disease and are receiving TB 
treatment.
FIGURE. Prevalence of HIV infection among newly registered TB patients,* by 






















AIDS, Tuberculosis, and Malaria also has been critical 
to the success of TB/HIV collaborative efforts. This 
funding has allowed MOPHS to hire additional staff 
members to support TB/HIV collaborative activi-
ties, and to ensure an uninterrupted supply of HIV 
rapid test kits, cotrimoxazole prophylaxis, ART, and 
monitoring and evaluation tools. 
Despite these efforts, provision of ART to persons 
with HIV during TB treatment remains at only 34%. 
Data from the region indicate that more than 90% 
of HIV-infected TB patients in Kenya likely meet 
the country’s CD4 count criteria for initiating ART 
(8), underscoring a large unmet need for treatment 
in this population.
The findings in this report are subject to at least 
two limitations. First, the number of HIV-infected 
TB patients receiving ART might have been underes-
timated. Some HIV-infected TB patients might have 
received ART late in TB treatment or after the end 
of TB treatment, and this information might not be 
captured by the extended TB surveillance system. No 
formal mechanism exists for transmitting informa-
tion from the HIV clinic that provides ART to the 
TB clinic that reports these data. Second, this report 
relies on surveillance data, which often are subject to 
reporting delays and might not reflect the most recent 
program performance.
Initiation of ART for persons with HIV during 
TB treatment has been shown to reduce mortality 
by approximately 50% (9). In 2009, WHO recom-
mended that all HIV-infected TB patients be started 
on ART regardless of CD4 count (5). Although 
Kenya’s ART-eligibility criteria have not yet been 
changed, MOPHS has been working to identify 
methods of increasing access to ART for TB patients. 
Integration of HIV testing and cotrimoxazole provi-
sion into TB clinics in Kenya has resulted in increases 
in testing and cotrimoxazole prophylaxis. Similar 
increases might result with ART if offered within 
the TB clinic and not at another clinical site. One 
high-volume TB clinic in rural Kenya has integrated 
provision of ART into the clinic, resulting in a four-
fold increase in ART initiation among HIV-infected 
TB patients (10). Additional strategies are needed 
to improve access to ART and strengthen linkages 
between TB clinics and HIV clinics to improve out-
comes for HIV-infected TB patients.
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An estimated 443,000 deaths in the United States 
occur each year as a result of cigarette smoking and 
exposure to secondhand smoke (1). These deaths cost 
the nation approximately $97 billion in lost produc-
tivity and $96 billion in health-care costs (1). During 
2000–2004 in Missouri, smoking caused 9,600 
deaths, 132,000 years of potential life lost (YPLL), 
$2.4 billion in productivity losses, and $2.2 billion 
in smoking-related health-care expenditures annu-
ally (2). To limit the adverse health consequences of 
tobacco use, states implement comprehensive tobacco 
control programs that identify disparities among 
population groups and target those disproportionately 
affected by tobacco use (3). This report compares 
the public health burden of smoking among whites 
and blacks in Missouri by estimating the number of 
smoking-attributable deaths and YPLL in these popu-
lation subgroups during 2003–2007. The findings 
indicate that the average annual smoking-attributable 
mortality (SAM) rate in the state was 18% higher 
for blacks (338 deaths per 100,000) than for whites 
(286 deaths per 100,000). The relative difference in 
smoking-attributable mortality rates between blacks 
and whites was larger for men (28%) than women 
(11%). For Missouri, these estimates provide an 
important benchmark for measuring the success of 
tobacco control programs in decreasing the burden 
of smoking-related diseases in these populations and 
reaffirm the need for full implementation of the state’s 
comprehensive tobacco control program (3).
The adult module of CDC’s Smoking-Attributable 
Mortality, Morbidity, and Economic Costs (SAMMEC) 
system* was used to calculate the SAM and YPLL rates 
for 19 disease categories.† Five-year average annual 
SAM and YPLL rates were computed from annual 
reports generated through SAMMEC. These estimates 
only cover deaths among persons aged ≥35 years. 
Deaths attributable to secondhand smoke or from 
smoking-related fires were not included. Sex-, race-, 
and age-specific smoking-attributable deaths were 
calculated by multiplying the total number of deaths 
in each of the 19 disease categories by the estimate of 
the smoking-attributable fraction (SAF) of deaths for 
each demographic group.§ These deaths were then 
grouped into three cause-of-death categories (malignant 
neoplasm, circulatory disease, and respiratory disease). 
Both races were assumed to have the same relative 
risk for dying from a particular disease among the 19 
disease categories attributable to smoking. Missouri 
data for 2003–2007 from the Behavioral Risk Factor 
Surveillance System (BRFSS) were used to estimate 
the age-, sex-, and race-specific annual prevalence of 
current and former smoking in the state.¶ Missouri 
death records for 2003–2007 were used to calculate the 
age-, sex-, race-, and disease-specific number of deaths 
each year (4). The life expectancy (average remaining 
years of life) by age group and sex was calculated using 
the abridged life table,** and absolute and relative 
disparity indexes were computed for each smoking-
related disease category (Tables 1–3) comparing SAM 
rates for blacks to SAM rates for whites. T-tests were 
used to evaluate the statistical significance (p≤0.05) of 
differences in SAM/YPLL rates between blacks and 
whites for the three major disease categories and major 
diseases.††
During 2003–2007, smoking caused an estimated 
average of 9,377 deaths (8,400 among whites and 853 
among blacks§§) annually among adults in Missouri 
Racial Disparities in Smoking-Attributable Mortality and Years of 
Potential Life Lost — Missouri, 2003–2007
* Available at http://apps.nccd.cdc.gov/sammec.
† Based on International Classification of Diseases, 10th Revision coding, 
including the following: malignant neoplasms: lip, oral cavity, pharynx 
(C00–C14), esophagus (C15), stomach (C16), pancreas (C25), 
larynx (C32), trachea, lung, bronchus (C33–C34), cervix uteri 
(C53), kidney and renal pelvis (C64–C65), urinary bladder (C67), 
and acute myeloid leukemia (C92.0); circulatory diseases: ischemic 
heart disease (I20–I25), other heart disease (I00–I09, I26–I51), 
cerebrovascular disease (I00–I69), atherosclerosis (I70–I71), aortic 
aneurysm (I71), and other arterial disease (I72–I78); respiratory 
diseases: pneumonia, influenza (J10–J18), bronchitis, emphysema 
(J40–J42, J43), and chronic airway obstruction (J44).
 § SAFs for each disease were calculated by using the following 
equation: SAF = [(p1(RR1) – 1) + p2(RR2 – 1)] / [p1(RR1 – 1) 
+ p2(RR2 – 1) + 1] where p1 = percentage of current smokers 
(persons who have smoked ≥100 cigarettes and now smoke every 
day or some days), p2 = percentage of former smokers (persons who 
have smoked ≥100 cigarettes and do not currently smoke), RR1 
= relative risk for current smokers relative to never smokers, and 
RR2 = relative risk for former smokers relative to never smokers.
 ¶ Available at http://www.cdc.gov/brfss/index.htm.
 ** Available at http://www.dhss.mo.gov/VitalStatistics.
 †† Absolute disparity = (SAM or YPLL) blacks - (SAM or YPLL) whites; 
relative disparity = {[(SAM or YPLL) blacks - (SAM or YPLL) whites] 
/ (SAM or YPLL) whites} × 100. 
 §§ Number of smoking-attributable deaths for groups other than 
blacks and whites could not be estimated because of small numbers; 
99.5% of deaths occurred among blacks and whites.
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(Table 1). An estimated 18.1% of deaths among 
persons aged ≥35 years in Missouri were the result 
of cigarette smoking (total number of deaths for this 
age group was 51,856). Smoking caused 32.1% of all 
deaths from cancer, 15.3% of all circulatory deaths, 
and 46.5% of all respiratory deaths in Missouri dur-
ing this period (4). In the cancer category, the major 
cause of death was cancer of the trachea, lung, or 
bronchus; in the circulatory category, the major cause 
was ischemic heart disease; and in the respiratory 
disease category, the major cause was chronic airway 
obstruction (Table 1). For both blacks and whites in 
Missouri, regardless of sex, the leading cause of SAM 
was cancer, followed by circulatory and respiratory 
diseases. 
Although SAM for blacks represented only 9.1% of 
the total SAM, the SAM rate for blacks in Missouri was 
18% higher than for whites (Table 2). This disparity 
TABLE 1. Average annual smoking-attributable deaths among persons aged ≥35 years, by cause of death,* sex, and race† — SAMMEC, 
Missouri, 2003–2007§
Cause of death (ICD-10 code) 
Smoking-attributable deaths
Among all Missouri residents White Black
Male Female Total Male Female Total Male Female Total
Total 5,642 3,735 9,377 5,071 3,329 8,400 523 329 853
Malignant neoplasm 2,561 1,374 3,935 2,291 1,206 3,497 253 134 387
Trachea, lung, bronchus (C33–C34) 1,984 1,165 3,149 1,784 1,031 2,815 186 110 297
Circulatory diseases 1,780 1,147 2,927 1,554 982 2,536 200 136 336
Ischemic heart disease (I20–I25) 1,138 670 1,808 1,002 577 1,579 119 77 197
Respiratory diseases 1,301 1,214 2,515 1,227 1,141 2,367 70 58 128
Chronic airway obstruction (J44) 1,013 987 2,000 958 932 1,890 51 45 96
Abbreviation: SAMMEC = Smoking-Attributable Mortality, Morbidity, and Economic Costs system.
* Based on International Classification of Diseases, 10th Revision coding, including the following: malignant neoplasms: lip, oral cavity, pharynx (C00–C14), esophagus 
(C15), stomach (C16), pancreas (C25), larynx (C32), trachea, lung, bronchus (C33–C34), cervix uteri (C53), kidney and renal pelvis (C64–C65), urinary bladder (C67), 
and acute myeloid leukemia (C92.0); circulatory diseases: ischemic heart disease (I20–I25), other heart disease (I00–I09, I26–I51), cerebrovascular disease (I00–I69), 
atherosclerosis (I70–I71), aortic aneurysm (I71), and other arterial disease (I72–I78); respiratory diseases: pneumonia, influenza (J10–J18), bronchitis, emphysema 
(J40–J42, J43), and chronic airway obstruction (J44). 
† The two races, black and white, constitute >96% of the population of Missouri. Number of smoking-attributable deaths for groups other than blacks and whites 
could not be estimated because of small numbers; 99.5% of deaths occurred among blacks and whites.
§ Based on 5-year annual average for 2003–2007. Does not include smoking-related fire deaths or secondhand smoke deaths. 
TABLE 2. Average annual SAM rates among persons aged ≥35 years, by cause of death,* sex, and race,† and racial disparity indexes — SAMMEC, 
Missouri, 2003–2007§
Cause of death (ICD-10 code) 
SAM rates (per 100,000 population) Racial disparity index¶
All Missouri residents White Black Absolute disparity Relative disparity (%)
Male Female Total Male Female Total Male Female Total Male Female Total Male Female Total
Total (per 100,000 population) 421 196 289 417 193 286 536 215 338 119 22 52 (28) (11) (18)
Malignant neoplasm 186 76 123 183 75 121 253 89 153 70 14 32 (38) (19) (26)
Trachea, lung, bronchus 
(C33–C34)
144 65 99 143 64 98 186 73 117 43 9 20 (30) (15) (20)
Circulatory diseases 133 57 89 128 54 85 200 87 130 72 33 45 (56) (61) (53)
Ischemic heart disease 
(I20–I25)
83 34 55 81 32 53 118 50 76 37 18 23 (45) (56) (44)
Respiratory diseases 102 63 78 105 65 80 82 40 54 -23 -25 -26 (-22) (-39) (-32)
Chronic airway obstruction 
(J44)
79 51 62 82 53 64 60 30 41 -22 -23 -23 (-27) (-43) (-36)
Abbreviations: SAM =  smoking-attributable mortality; SAMMEC = Smoking-Attributable Mortality, Morbidity, and Economic Costs system; YPLL = years of potential 
life lost.
* Based on International Classification of Diseases, 10th Revision coding, including the following: malignant neoplasms: lip, oral cavity, pharynx (C00–C14), esophagus 
(C15), stomach (C16), pancreas (C25), larynx (C32), trachea, lung, bronchus (C33–C34), cervix uteri (C53), kidney and renal pelvis (C64–C65), urinary bladder (C67), 
and acute myeloid leukemia (C92.0); circulatory diseases: ischemic heart disease (I20–I25), other heart disease (I00–I09, I26–I51), cerebrovascular disease (I00–I69), 
atherosclerosis (I70–I71), aortic aneurysm (I71), and other arterial disease (I72–I78); respiratory diseases: pneumonia, influenza (J10–J18), bronchitis, emphysema 
(J40–J42, J43), and chronic airway obstruction (J44).
† The two races, black and white, constitute >96% of the population of Missouri. Number of smoking-attributable deaths for groups other than blacks and whites 
could not be estimated because of small numbers; 99.5% of deaths occurred among blacks and whites.
§ Based on 5-year annual average for 2003–2007.  Does not include smoking-related fire deaths or secondhand smoke deaths.
¶ Absolute disparity = (SAM or YPLL) blacks  - (SAM or YPLL) whites; relative disparity = {[(SAM or YPLL) blacks - (SAM or YPLL) whites] / (SAM or YPLL) whites} × 100. The dif-
ference in the SAM/YPLL rates of blacks and whites is statistically significant by t-test (p≤0.05) for the three categories and major diseases. 
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was larger (28%) for black men than for black women 
(11%). SAM rates for blacks were 26% higher than 
for whites for malignant neoplasm and 53% higher 
for circulatory diseases but 32% lower for respiratory 
diseases. 
The smoking-attributable YPLL rate for blacks 
also was 18% higher than for whites and differed most 
for men. Black men had a YPLL rate 25% higher than 
white men, and the rate for black women was 15% 
higher than for white women (Table 3). Similar to the 
SAM results, the YPLL rates for the three major disease 
categories showed that the YPLL rates for blacks were 
higher than for whites for malignant neoplasm and 
circulatory diseases but lower for respiratory diseases. 
The YPLL rate resulting from smoking-related cancer 
deaths for blacks was 19% higher than for whites, but 
26% higher for the SAM rate. For circulatory deaths, 
the YPLL rate for blacks was 54% higher, similar to 
the disparity in the SAM rate (53%). For respiratory 
diseases, the YPLL rate for blacks was 33% lower than 
for whites, and similarly, 32% lower for the SAM rate. 
For specific diseases, blacks had a 14% higher YPLL 
rate for lung cancer, 35% higher rate for ischemic 
heart disease, and 38% lower rate for chronic airway 
obstruction than whites. 
Reported by
N Kayani, PhD, SG Homan, PhD, S Yun, MD, PhD, 
Missouri Dept of Health and Senior Svcs. A Malarcher, 
PhD, Office on Smoking and Health, CDC. 
Editorial Note
This is the first study to provide data on racial 
disparities in SAM and YPLL using SAMMEC. 
These data are valuable for Missouri’s tobacco 
control program for documenting and evaluating 
changes in tobacco-related racial disparities in the 
state. Additional studies are needed to explain why 
Missouri blacks are more likely to die from smoking-
related cancers and circulatory diseases than whites, 
but less likely to die from smoking-related respiratory 
diseases. 
Variations in smoking-related mortality exist across 
states and occur because of differences in population 
demographics and tobacco use. Differences in other 
tobacco-use–related behaviors, variations in tobacco 
control programs and policies, and tobacco industry 
marketing also exist (5). Racial and ethnic dispari-
ties in smoking-related morbidity and mortality also 
are associated with socioeconomic status, cigarette 
smoking patterns, and differences in biologic and 
genetic factors; for example, smoking initiation and 
TABLE 3. Average annual smoking-attributable YPLL among persons aged ≥35 years, by cause of death,* sex, and race,† and racial disparity 
indexes — SAMMEC, Missouri, 2003–2007§
Cause of death (ICD-10 code) 
Smoking-attributable YPLL rates (per 100,000 population) Racial disparity index¶
All Missouri residents White Black Absolute disparity Relative disparity (%)
Male Female Total Male Female Total Male Female Total Male Female Total Male Female Total
Total (per 100,000 population) 5,741 3,147 4,301 5,720 3,136 4,292 7,165 3,601 5,048 1,445 465 756 (25) (15) (18)
Malignant neoplasm 2,676 1,366 1,952 2,664 1,354 1,944 3,461 1,519 2,313 796 165 369 (30) (12) (19)
Trachea, lung, bronchus 
(C33–C34)
2,054 1,170 1,563 2,056 1,169 1,565 2,534 1,264 1,782 478 95 216 (23) (8) (14)
Circulatory diseases 1,952 925 1,393 1,887 870 1,336 2,820 1,527 2,058 934 656 723 (49) (75) (54)
Ischemic heart disease 
(I20–I25)
1,310 538 896 1,288 518 877 1,690 812 1,181 402 294 304 (31) (57) (35)
Respiratory diseases 1,113 856 957 1,169 912 1,013 884 555 677 -285 -357 -336 (-24) (-39) (-33)
Chronic airway obstruction 
(J44)
864 704 765 910 756 814 640 428 506 -270 -328 -308 (-30) (-43) (-38)
Abbreviations: SAM =  smoking-attributable mortality; SAMMEC = Smoking-Attributable Mortality, Morbidity, and Economic Costs system; YPLL = years of potential 
life lost.
* Based on International Classification of Diseases, 10th Revision coding, including the following: malignant neoplasms: lip, oral cavity, pharynx (C00–C14), esophagus 
(C15), stomach (C16), pancreas (C25), larynx (C32), trachea, lung, bronchus (C33–C34), cervix uteri (C53), kidney and renal pelvis (C64–C65), urinary bladder (C67), 
and acute myeloid leukemia (C92.0); circulatory diseases: ischemic heart disease (I20–I25), other heart disease (I00–I09, I26–I51), cerebrovascular disease (I00–I69), 
atherosclerosis (I70–I71), aortic aneurysm (I71), and other arterial disease (I72–I78); respiratory diseases: pneumonia, influenza (J10–J18), bronchitis, emphysema 
(J40–J42, J43), and chronic airway obstruction (J44).
† The two races, black and white, constitute >96% of the population of Missouri. Number of smoking-attributable deaths for groups other than blacks and whites 
could not be estimated because of small numbers; 99.5% of deaths occurred among blacks and whites.
§ Based on 5-year annual average for 2003–2007.  Does not include smoking-related fire deaths or secondhand smoke deaths.
¶ Absolute disparity = (SAM or YPLL) blacks  - (SAM or YPLL) whites; relative disparity = {[(SAM or YPLL) blacks - (SAM or YPLL) whites] / (SAM or YPLL) whites} × 100. The dif-
ference in the SAM/YPLL rates of blacks and whites is statistically significant by t-test (p≤0.05) for the three categories and major diseases. 
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cessation rates vary by race, as does nicotine metabo-
lism and disease outcomes among cigarette smokers 
(6). Significant racial disparities in SAM existed in 
Missouri during 2003–2007, with an average of 52 
per 100,000 more black adults dying each year from 
cigarette smoking than white adults, reflecting an 
18% higher SAM rate among blacks than whites. 
Smoking-attributable YPLL also were 18% higher 
among blacks than whites. 
SAM during 2003–2007 reflects smoking patterns 
of the past 40 years. Although the smoking prevalence 
among blacks and whites in Missouri fluctuated 
during the past 2 decades, blacks tended to have a 
higher smoking prevalence than whites. The amount 
and duration of smoking and brands or types of ciga-
rettes used also could contribute to disparities (7,8). 
However, data on these types of smoking patterns 
were not captured in Missouri’s tobacco use surveil-
lance systems. More research is needed to explore the 
causes of these disparities. 
Smoking prevalence declined by 26.3% among 
white adults and 25.8% among black adults in 
Missouri during 1995–2009. In 2009, the smoking 
prevalence was 27.1% among black adults and was 
22.1% among white adults. Among youths, smoking 
prevalence in Missouri declined during 1995–2009, 
to 19.4% in whites and 15.7% in blacks.¶¶ During 
the entire period, smoking prevalence among black 
young adults (aged 18–24 years) remained lower than 
for white young adults, but the prevalence of smok-
ing among persons aged 35–44 years of either race 
was similar. The late initiation of tobacco use among 
black youths and black young adults suggests that 
the current racial disparities in smoking-associated 
morbidity and mortality in Missouri might change in 
the future; continued surveillance of youth and young 
adult smoking is needed because of this later initiation 
of smoking among blacks. Continued implementa-
tion of effective population-based tobacco control 
interventions that discourage initiation and increase 
cessation among youths and adults also is needed to 
prevent smoking-related morbidity and mortality in 
the next several decades (3,8).
In 2006, the Missouri Comprehensive Tobacco 
Use Prevention Program identified disparities in 
tobacco use, and the state disparities work group 
created a strategic plan for addressing the identified 
disparities. The plan was incorporated into Missouri’s 
2006–2009 and 2010–2014 comprehensive tobacco 
control plans. The Missouri Comprehensive Tobacco 
Control Program supports the Missouri Tobacco 
Quitline to help smokers (especially low-income 
smokers) quit smoking, and hosts a website that can 
assist public health agencies in developing interven-
tions to reduce the health impact of and disparities 
in tobacco use.*** The quitline will continue to play 
a role in reducing racial disparities in smoking and 
smoking-related morbidity and mortality in Missouri. 
An analysis of 2005–2009 Missouri quitline data 
showed that slightly higher percentages of black 
smokers than white smokers were calling the quitline; 
black smokers comprised 12.6% of all smokers, but 
the quitline received 14.0% of all calls from black 
smokers. 
The findings of this report are subject to at least 
four limitations. First, SAMMEC uses estimates of 
current year’s smoking to estimate SAM; however, 
current prevalence estimates do not adequately reflect 
smoking patterns in past decades when the smoking 
prevalence was higher. These estimates also do not 
account for deaths associated with cigar and pipe 
smoking, the use of smokeless tobacco, secondhand 
smoke, smoking-related fires, and deaths among per-
sons aged <35 years. Second, SAM rates for groups 
 ¶¶ Available at http://apps.nccd.cdc.gov/youthonline/app/
questionsorlocations.aspx?categoryid=2.
What is already known on this topic? 
Although disparities in smoking prevalence among 
blacks and whites are well documented, no study has 
shown differences in health outcomes in terms of 
smoking-attributable mortality (SAM). 
What is added by this report? 
Using 2003–2007 Missouri data and attributable risk 
calculations, this study identified significant racial 
disparities in SAM, with an average of 52 per 100,000 
more black adults dying each year from cigarette 
smoking than white adults, reflecting an 18% larger 
SAM rate among blacks than whites. 
What are the implications for public health practice? 
States should continue to implement population-
wide tobacco control interventions (e.g., quitlines, 
smoke-free policies, and increased excise taxes on 
tobacco products) that reach all racial groups, and 
implement targeted strategies for high-risk groups 
to decrease disparities in tobacco use and related 
mortality.
 *** Available at http://www.dhss.mo.gov/CHIR.
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other than blacks and whites in Missouri could not be 
estimated accurately because of the small numbers of 
deaths; however, 99.5% of deaths from the 19 disease 
categories considered in this report were among blacks 
and whites. Third, the same relative risks for dying 
from a particular disease among the 19 disease cat-
egories attributable to smoking for current and former 
smokers were used for blacks and for whites, although 
relative risk might be different between blacks and 
whites. Preferences for types and brands of cigarettes as 
well as smoking intensity and duration differ between 
white and blacks and might result in differing relative 
risks. Finally, relative risk was adjusted for the effects of 
age but not for other potential confounders. However, 
research suggests that education, alcohol use, and 
other confounders had negligible additional effects 
on SAM estimates for lung cancer, chronic obstruc-
tive pulmonary disease, ischemic heart disease, and 
cerebrovascular disease (9). 
Effective population-wide interventions (e.g., 
increasing the price of tobacco products through 
excise tax and implementing smoke-free policies) 
appear to reach all segments of the population; 
however, targeted strategies might still be needed 
for certain high-risk groups (e.g., persons with lower 
socioeconomic status or educational attainment) to 
reduce disparities (3,10). Race-specific SAM measures 
and race-specific trends in youth and adult smok-
ing prevalence can be used to document and assess 
progress in eliminating tobacco-related disparities 
within a state.
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pdf. Accesssed November 18, 2010.
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2009 Chronic Disease Epidemiology 
Capacity: Findings and Recommendations 
Available Online
The Council of State and Territorial Epidemiologists 
(CSTE) has released a new report on state-based 
chronic disease epidemiology capacity in the United 
States. The report, Chronic Disease Epidemiology 
Capacity: Findings and Recommendations, an update 
from the 2004 report (1), provides findings from the 
2009 CSTE national assessment (2) and recommen-
dations for improving capacity.
The report notes that 53% of jurisdictions (all 50 
states and the District of Columbia) reported at least 
substantial chronic disease epidemiology capacity 
in 2009 and more quality-level work is being con-
ducted than in previous years. However, nearly half 
of the jurisdictions lack substantial capacity, and the 
percentage of jurisdictions with little or no chronic 
disease epidemiology capacity increased progressively 
during 2001–2009. A major recommendation is that 
improving capacity in jurisdictions with little or no 
chronic disease epidemiology capacity should be a 
priority. 
The report is available online at http://www.
cste.org/2009chroniceca.pdf. Additional informa-
tion or printed copies are available from CSTE 
by e-mail (jlemmings@cste.org) or telephone 
(770-458-3811). 
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QuickStats 
FROM THE NATIONAL CENTER FOR HEALTH STATISTICS
Infant Mortality Rates* for Single Births, by Age Group of Mother — 
United States, 2006
In 2006, infant mortality rates were highest for mothers in the youngest and oldest age groups. The infant mortality rate for single 
births to mothers aged <15 years was 16.7 infant deaths per 1,000 live births, approximately three times the rates for mothers 
aged 25–29 years (5.1), 30–34 years (4.5), and 35–39 years (5.2), the age groups at lowest risk. The infant mortality rate for single 
births to mothers aged ≥45 years was 11.46, approximately twice the rate for mothers in the three age groups at lowest risk.
Sources: National Center for Health Statistics. Linked birth/infant death data set, 2006. Available at http://www.cdc.gov/nchs/linked.htm. 




















* Per 1,000 live births.
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TABLE I. Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending 









Total cases reported 
for previous years States reporting cases 
during current week (No.)2009 2008 2007 2006 2005
Anthrax — — — 1 — 1 1 —
Botulism, total 3 87 3 118 145 144 165 135
foodborne — 6 1 10 17 32 20 19
infant 3 61 2 83 109 85 97 85 PA (2), WA (1)
other (wound and unspecified) — 20 1 25 19 27 48 31
Brucellosis 1 111 2 115 80 131 121 120 CA (1)
Chancroid 1 35 1 28 25 23 33 17 NY (1)
Cholera — 5 0 10 5 7 9 8
Cyclosporiasis§ 1 163 1 141 139 93 137 543 FL (1)
Diphtheria — — — — — — — —
Domestic arboviral diseases § ,¶:
California serogroup virus disease — 63 0 55 62 55 67 80
Eastern equine encephalitis virus disease — 10 — 4 4 4 8 21
Powassan virus disease — 5 0 6 2 7 1 1
St. Louis encephalitis virus disease — 7 0 12 13 9 10 13
Western equine encephalitis virus disease — — — — — — — —
Haemophilus influenzae,** invasive disease (age <5 yrs):
serotype b — 14 0 35 30 22 29 9
nonserotype b — 132 3 236 244 199 175 135
unknown serotype 8 226 3 178 163 180 179 217 NY (2), PA (1), OH (1), NC (1), GA (1), ID (1), CA (1)
Hansen disease§ 1 56 2 103 80 101 66 87 AR (1)
Hantavirus pulmonary syndrome§ — 17 0 20 18 32 40 26
Hemolytic uremic syndrome, postdiarrheal§ 4 203 4 242 330 292 288 221 NY (2), MD (1), OK (1)
HIV infection, pediatric (age <13 yrs)†† — — 2 — — — — 380
Influenza-associated pediatric mortality§,§§ — 58 5 358 90 77 43 45
Listeriosis 6 683 15 851 759 808 884 896 PA (1), OH (2), FL (1), CA (2)
Measles¶¶ — 56 0 71 140 43 55 66
Meningococcal disease, invasive***:
A, C, Y, and W-135 4 211 5 301 330 325 318 297 NC (1), TX (3)
serogroup B — 95 3 174 188 167 193 156
other serogroup — 8 0 23 38 35 32 27
unknown serogroup 8 352 10 482 616 550 651 765 ME (1), OH (2), FL (1), CO (1), CA (3)
Mumps 6 2,469 30 1,991 454 800 6,584 314 OH (2), MI (1), TX (2), CA (1)
Novel influenza A virus infections††† 1 3 0 43,774 2 4 NN NN WI (1)
Plague — 2 0 8 3 7 17 8
Poliomyelitis, paralytic — — — 1 — — — 1
Polio virus Infection, nonparalytic§ — — — — — — NN NN
Psittacosis§ — 4 0 9 8 12 21 16
Q fever, total§,§§§ 2 104 2 114 120 171 169 136
acute 2 80 1 94 106 — — — NY (1), CA (1)
chronic — 24 0 20 14 — — —
Rabies, human — 1 0 4 2 1 3 2
Rubella¶¶¶ — 6 0 3 16 12 11 11
Rubella, congenital syndrome — — — 2 — — 1 1
SARS-CoV§,**** — — — — — — — —
Smallpox§ — — — — — — — —
Streptococcal toxic-shock syndrome§ — 143 1 161 157 132 125 129
Syphilis, congenital (age <1 yr)†††† — 189 7 423 431 430 349 329
Tetanus — 7 0 18 19 28 41 27
Toxic-shock syndrome (staphylococcal)§ 1 68 1 74 71 92 101 90 OH (1)
Trichinellosis — 4 0 13 39 5 15 16
Tularemia — 99 1 93 123 137 95 154
Typhoid fever 5 369 4 397 449 434 353 324 TX (1), CA (4)
Vancomycin-intermediate Staphylococcus aureus§ 3 81 1 78 63 37 6 2 NY (1), FL (2)
Vancomycin-resistant Staphylococcus aureus§ — 1 — 1 — 2 1 3
Vibriosis (noncholera Vibrio species infections)§ 6 697 7 789 588 549 NN NN MD (1), FL (4), AZ (1)
Viral hemorrhagic fever§§§§ — 1 — NN NN NN NN NN
Yellow fever — — — — — — — —
See Table I footnotes on next page.
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Notifiable Disease Data Team and 122 Cities Mortality Data Team
 Patsy A. Hall-Baker
Deborah A. Adams  Rosaline Dhara
Willie J. Anderson  Pearl C. Sharp
Michael S. Wodajo  Lenee Blanton
* Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the 
past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week 
totals.
FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week 


























TABLE I. (Continued) Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week 
ending November 20, 2010 (46th week)*
—: No reported cases. N: Not reportable. NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts.
 * Case counts for reporting year 2010 are provisional and subject to change.  For further information on interpretation of these data, see http://www.cdc.gov/ncphi/disss/nndss/phs/files/
ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf.
 † Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. 
Additional information is available at http://www.cdc.gov/ncphi/disss/nndss/phs/files/5yearweeklyaverage.pdf.
 § Not reportable in all states. Data from states where the condition is not reportable are excluded from this table except starting in 2007 for the domestic arboviral diseases, STD data, TB 
data, and influenza-associated pediatric mortality, and in 2003 for SARS-CoV.  Reporting exceptions are available at http://www.cdc.gov/ncphi/disss/nndss/phs/infdis.htm.
 ¶ Includes both neuroinvasive and nonneuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and 
Enteric Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II.
 ** Data for H. influenzae (all ages, all serotypes) are available in Table II.
 †† Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Implementation of HIV reporting influences 
the number of cases reported. Updates of pediatric HIV data have been temporarily suspended until upgrading of the national HIV/AIDS surveillance data management system is 
completed. Data for HIV/AIDS, when available, are displayed in Table IV, which appears quarterly.
 §§ Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. Since October 3, 2010, one influenza-associated pediatric death 
occurred during the 2010–11 influenza season. Since August 30, 2009, a total of 282 influenza-associated pediatric deaths occurring during the 2009–10 influenza season have been 
reported. 
 ¶¶ No measles cases were reported for the current week.
 *** Data for meningococcal disease (all serogroups) are available in Table II.
 ††† CDC discontinued reporting of individual confirmed and probable cases of 2009 pandemic influenza A (H1N1) virus infections on July 24, 2009. During 2009, four cases of human 
infection with novel influenza A viruses, different from the 2009 pandemic influenza A (H1N1) strain, were reported to CDC. The three cases of novel influenza A virus infection reported 
to CDC during 2010 were identified as swine influenza A (H3N2) virus and are unrelated to the 2009 pandemic influenza A (H1N1) virus. Total case counts for 2009 were provided by the 
Influenza Division, National Center for Immunization and Respiratory Diseases (NCIRD).
 §§§ In 2009, Q fever acute and chronic reporting categories were recognized as a result of revisions to the Q fever case definition. Prior to that time, case counts were not differentiated with 
respect to acute and chronic Q fever cases.
 ¶¶¶ No rubella cases were reported for the current week.
 **** Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases.
 †††† Updated weekly from reports to the Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.
 §§§§ There was one case of viral hemorrhagic fever reported during week 12. The one case report was confirmed as lassa fever. See Table II for dengue hemorrhagic fever.
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TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending November 20, 2010, and November 21, 2009 (46th week)*
Reporting area
Chlamydia trachomatis infection Cryptosporidiosis
Current  
week






Previous 52 weeks Cum  
2010
Cum  
2009Med Max Med Max
United States 9,338 23,719 26,215 1,056,024 1,110,577 57 121 339 6,903 6,712
New England 547 759 1,396 35,306 35,754 1 7 74 418 423
Connecticut — 216 736 8,917 10,328 — 0 68 68 38
Maine† — 50 69 1,996 2,165 — 1 7 74 46
Massachusetts 445 398 698 18,115 16,980 1 3 8 148 166
New Hampshire 40 42 114 2,167 1,906 — 1 5 49 76
Rhode Island† 62 64 120 3,031 3,302 — 0 2 13 22
Vermont† — 23 51 1,080 1,073 — 1 5 66 75
Mid. Atlantic 1,661 3,347 4,893 149,983 140,595 5 14 37 725 746
New Jersey — 480 691 21,905 21,789 — 0 1 — 49
New York (Upstate) 1,025 688 2,530 31,023 27,986 3 3 16 195 195
New York City — 1,210 2,739 54,775 52,276 — 2 5 86 74
Pennsylvania 636 917 1,092 42,280 38,544 2 8 26 444 428
E.N. Central 885 3,468 4,127 153,494 178,130 10 30 122 1,865 1,578
Illinois — 801 1,225 32,104 54,671 — 4 21 265 145
Indiana — 364 796 16,615 19,872 — 3 10 140 261
Michigan 594 913 1,419 42,863 41,154 — 5 18 298 260
Ohio 154 972 1,085 43,101 43,606 7 7 24 423 349
Wisconsin 137 424 511 18,811 18,827 3 9 55 739 563
W.N. Central 442 1,348 1,565 59,810 63,275 4 21 83 1,221 1,025
Iowa — 191 269 8,703 8,559 — 4 24 315 192
Kansas 46 189 235 8,498 9,583 — 2 9 123 96
Minnesota — 278 331 11,424 12,906 — 0 16 98 314
Missouri 396 504 603 23,013 23,189 2 4 30 351 175
Nebraska† — 93 237 4,037 4,767 2 2 26 219 111
North Dakota — 31 89 1,436 1,601 — 0 18 30 12
South Dakota — 61 77 2,699 2,670 — 2 6 85 125
S. Atlantic 1,901 4,695 5,681 211,487 224,882 14 18 51 912 1,039
Delaware 73 84 220 3,893 4,203 — 0 2 7 9
District of Columbia 60 96 177 4,320 6,068 — 0 1 3 6
Florida 576 1,460 1,737 66,289 65,791 5 7 19 338 415
Georgia 246 582 1,229 25,784 36,141 4 5 31 274 317
Maryland† 345 460 1,031 20,573 20,102 — 1 3 33 39
North Carolina — 765 1,562 35,595 37,058 4 0 12 73 106
South Carolina† — 529 763 24,027 24,165 — 1 8 81 56
Virginia† 601 596 902 27,671 28,070 1 2 8 87 75
West Virginia — 72 112 3,335 3,284 — 0 3 16 16
E.S. Central 219 1,718 2,415 77,151 84,229 1 4 19 295 211
Alabama† — 491 757 22,345 23,752 — 2 12 142 61
Kentucky — 269 614 12,749 12,149 1 1 6 79 61
Mississippi — 377 780 16,742 21,453 — 0 3 22 17
Tennessee† 219 574 738 25,315 26,875 — 1 5 52 72
W.S. Central 591 3,003 4,578 138,336 144,441 2 8 39 400 515
Arkansas† 170 267 392 10,851 12,959 — 0 3 31 51
Louisiana — 245 1,077 12,856 24,754 — 1 6 59 53
Oklahoma 421 261 1,374 13,493 12,771 2 1 8 78 115
Texas† — 2,205 3,194 101,136 93,957 — 5 30 232 296
Mountain 603 1,440 1,904 65,157 71,365 2 10 29 503 519
Arizona 312 498 713 21,566 23,122 — 0 3 33 33
Colorado — 356 560 15,087 17,747 2 2 8 128 131
Idaho† — 69 200 3,396 3,402 — 2 7 87 83
Montana† — 60 82 2,670 2,699 — 1 4 46 52
Nevada† 22 175 337 8,247 8,915 — 0 6 31 25
New Mexico† 219 152 453 6,979 8,220 — 2 11 104 138
Utah 20 121 176 5,477 5,500 — 1 5 58 37
Wyoming† 30 36 79 1,735 1,760 — 0 2 16 20
Pacific 2,489 3,677 5,350 165,300 167,906 18 11 28 564 656
Alaska 17 113 148 5,081 4,643 — 0 1 4 6
California 1,982 2,784 4,406 126,887 128,554 17 7 19 333 393
Hawaii — 112 158 5,099 5,465 — 0 0 — 1
Oregon 156 209 468 9,794 9,952 — 3 13 156 176
Washington 334 399 500 18,439 19,292 1 1 8 71 80
Territories
American Samoa — 0 0 — — N 0 0 N N
C.N.M.I. — — — — — — — — — —
Guam — 6 31 259 327 — 0 0 — —
Puerto Rico 104 92 265 4,888 6,654 N 0 0 N N
U.S. Virgin Islands — 10 29 323 460 — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Case counts for reporting year 2010 are provisional and subject to change. For further information on interpretation of these data, see http://www.cdc.gov/ncphi/disss/nndss/phs/files/
ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf. Data for HIV/AIDS, AIDS and TB, when available, are displayed in Table IV, which appears quarterly.
† Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending November 20, 2010, and November 21, 2009 (46th week)*
Dengue Virus Infection
Reporting area
Dengue Fever† Dengue Hemorrhagic Fever§
Current  
week






Previous 52 weeks Cum  
2010
Cum  
2009Med Max Med Max
United States — 5 30 394 NN — 0 1 4 NN
New England — 0 2 6 NN — 0 0 — NN
Connecticut — 0 0 — NN — 0 0 — NN
Maine¶ — 0 2 5 NN — 0 0 — NN
Massachusetts — 0 0 — NN — 0 0 — NN
New Hampshire — 0 0 — NN — 0 0 — NN
Rhode Island¶ — 0 0 — NN — 0 0 — NN
Vermont¶ — 0 1 1 NN — 0 0 — NN
Mid. Atlantic — 1 9 78 NN — 0 0 — NN
New Jersey — 0 0 — NN — 0 0 — NN
New York (Upstate) — 0 0 — NN — 0 0 — NN
New York City — 0 7 63 NN — 0 0 — NN
Pennsylvania — 0 2 15 NN — 0 0 — NN
E.N. Central — 0 5 40 NN — 0 1 1 NN
Illinois — 0 0 — NN — 0 0 — NN
Indiana — 0 2 11 NN — 0 0 — NN
Michigan — 0 2 9 NN — 0 0 — NN
Ohio — 0 2 15 NN — 0 0 — NN
Wisconsin — 0 2 5 NN — 0 1 1 NN
W.N. Central — 0 2 17 NN — 0 0 — NN
Iowa — 0 1 2 NN — 0 0 — NN
Kansas — 0 1 1 NN — 0 0 — NN
Minnesota — 0 2 13 NN — 0 0 — NN
Missouri — 0 0 — NN — 0 0 — NN
Nebraska¶ — 0 0 — NN — 0 0 — NN
North Dakota — 0 1 1 NN — 0 0 — NN
South Dakota — 0 0 — NN — 0 0 — NN
S. Atlantic — 2 17 205 NN — 0 1 2 NN
Delaware — 0 0 — NN — 0 0 — NN
District of Columbia — 0 0 — NN — 0 0 — NN
Florida — 2 14 166 NN — 0 1 2 NN
Georgia — 0 2 11 NN — 0 0 — NN
Maryland¶ — 0 0 — NN — 0 0 — NN
North Carolina — 0 1 4 NN — 0 0 — NN
South Carolina¶ — 0 3 10 NN — 0 0 — NN
Virginia¶ — 0 3 12 NN — 0 0 — NN
West Virginia — 0 1 2 NN — 0 0 — NN
E.S. Central — 0 2 5 NN — 0 0 — NN
Alabama¶ — 0 2 2 NN — 0 0 — NN
Kentucky — 0 1 1 NN — 0 0 — NN
Mississippi — 0 1 1 NN — 0 0 — NN
Tennessee¶ — 0 1 1 NN — 0 0 — NN
W.S. Central — 0 1 4 NN — 0 1 1 NN
Arkansas¶ — 0 0 — NN — 0 1 1 NN
Louisiana — 0 0 — NN — 0 0 — NN
Oklahoma — 0 1 4 NN — 0 0 — NN
Texas¶ — 0 0 — NN — 0 0 — NN
Mountain — 0 2 16 NN — 0 0 — NN
Arizona — 0 1 6 NN — 0 0 — NN
Colorado — 0 0 — NN — 0 0 — NN
Idaho¶ — 0 1 2 NN — 0 0 — NN
Montana¶ — 0 1 3 NN — 0 0 — NN
Nevada¶ — 0 1 4 NN — 0 0 — NN
New Mexico¶ — 0 1 1 NN — 0 0 — NN
Utah — 0 0 — NN — 0 0 — NN
Wyoming¶ — 0 0 — NN — 0 0 — NN
Pacific — 0 5 23 NN — 0 0 — NN
Alaska — 0 0 — NN — 0 0 — NN
California — 0 5 11 NN — 0 0 — NN
Hawaii — 0 0 — NN — 0 0 — NN
Oregon — 0 0 — NN — 0 0 — NN
Washington — 0 2 12 NN — 0 0 — NN
Territories
American Samoa — 0 0 — NN — 0 0 — NN
C.N.M.I. — — — — NN — — — — NN
Guam — 0 0 — NN — 0 0 — NN
Puerto Rico — 106 535 9,366 NN — 0 3 33 NN
U.S. Virgin Islands — 0 0 — NN — 0 0 — NN
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Case counts for reporting year 2010 are provisional and subject to change. For further information on interpretation of these data, see http://www.cdc.gov/ncphi/disss/nndss/phs/files/
ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf. Data for HIV/AIDS, AIDS and TB, when available, are displayed in Table IV, which appears quarterly.
† Dengue Fever includes cases that meet criteria for Dengue Fever with hemorrhage, other clinical, and unknown case classifications. 
§ DHF includes cases that meet criteria for dengue shock syndrome (DSS), a more severe form of DHF.
¶ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending November 20, 2010, and November 21, 2009 (46th week)*
Ehrlichiosis/Anaplasmosis†
Reporting area
Ehrlichia chaffeensis Anaplasma phagocytophilum Undetermined
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 8 8 181 558 887 8 11 309 706 860 1 1 35 95 160
New England 1 0 2 5 52 — 1 8 79 251 — 0 2 7 2
Connecticut — 0 0 — — — 0 5 23 17 — 0 2 5 —
Maine§ 1 0 1 3 5 — 0 2 16 14 — 0 0 — —
Massachusetts — 0 0 — 9 — 0 2 — 93 — 0 0 — —
New Hampshire — 0 1 2 4 — 0 3 16 18 — 0 1 2 1
Rhode Island§ — 0 1 — 33 — 0 7 24 109 — 0 0 — 1
Vermont§ — 0 0 — 1 — 0 0 — — — 0 0 — —
Mid. Atlantic — 1 15 48 184 5 2 17 188 296 — 0 2 4 44
New Jersey — 0 2 — 98 — 0 1 1 70 — 0 0 — —
New York (Upstate) — 0 15 28 51 5 2 17 184 217 — 0 1 4 6
New York City — 0 3 19 10 — 0 1 3 8 — 0 0 — 1
Pennsylvania — 0 1 1 25 — 0 1 — 1 — 0 1 — 37
E.N. Central — 0 4 32 83 — 3 39 347 269 — 1 7 61 71
Illinois — 0 2 12 33 — 0 1 5 6 — 0 2 3 3
Indiana — 0 0 — — — 0 0 — — — 0 3 27 36
Michigan — 0 1 2 5 — 0 0 — — — 0 1 4 —
Ohio — 0 3 6 13 — 0 1 2 1 — 0 0 — 2
Wisconsin — 0 1 12 32 — 3 39 340 262 — 0 4 27 30
W.N. Central — 1 13 117 153 — 0 261 12 21 1 0 30 10 16
Iowa — 0 0 — — — 0 0 — — — 0 0 — —
Kansas — 0 1 6 6 — 0 0 — 1 — 0 0 — —
Minnesota — 0 6 — 2 — 0 261 — 15 — 0 30 — 3
Missouri — 1 13 109 143 — 0 3 12 4 1 0 3 10 13
Nebraska§ — 0 1 2 2 — 0 0 — 1 — 0 0 — —
North Dakota — 0 0 — — — 0 0 — — — 0 0 — —
South Dakota — 0 0 — — — 0 0 — — — 0 0 — —
S. Atlantic 3 4 19 246 249 — 1 7 57 17 — 0 1 6 2
Delaware — 0 3 17 21 — 0 1 4 2 — 0 0 — —
District of Columbia — 0 0 — — — 0 0 — — — 0 0 — —
Florida — 0 2 8 11 — 0 1 3 3 — 0 0 — —
Georgia — 0 4 22 18 — 0 1 2 1 — 0 1 1 —
Maryland§ — 0 3 23 40 — 0 2 15 4 — 0 1 2 —
North Carolina 1 2 13 100 61 — 0 4 21 3 — 0 0 — —
South Carolina§ — 0 2 3 11 — 0 1 1 — — 0 0 — —
Virginia§ 2 1 13 72 86 — 0 2 11 4 — 0 1 3 2
West Virginia — 0 1 1 1 — 0 0 — — — 0 1 — —
E.S. Central — 1 10 85 133 1 0 2 18 3 — 0 1 6 24
Alabama§ — 0 3 11 8 — 0 2 7 1 — 0 0 — —
Kentucky — 0 2 16 12 — 0 0 — — — 0 0 — —
Mississippi — 0 1 3 6 — 0 1 1 — — 0 0 — —
Tennessee§ — 0 6 55 107 1 0 2 10 2 — 0 1 6 24
W.S. Central 4 0 141 24 30 2 0 23 5 1 — 0 1 1 —
Arkansas§ 4 0 34 6 4 2 0 6 2 — — 0 0 — —
Louisiana — 0 1 1 — — 0 0 — — — 0 0 — —
Oklahoma — 0 105 14 24 — 0 16 2 1 — 0 0 — —
Texas§ — 0 2 3 2 — 0 1 1 — — 0 1 1 —
Mountain — 0 0 — — — 0 0 — — — 0 0 — 1
Arizona — 0 0 — — — 0 0 — — — 0 0 — 1
Colorado — 0 0 — — — 0 0 — — — 0 0 — —
Idaho§ — 0 0 — — — 0 0 — — — 0 0 — —
Montana§ — 0 0 — — — 0 0 — — — 0 0 — —
Nevada§ — 0 0 — — — 0 0 — — — 0 0 — —
New Mexico§ — 0 0 — — — 0 0 — — — 0 0 — —
Utah — 0 0 — — — 0 0 — — — 0 0 — —
Wyoming§ — 0 0 — — — 0 0 — — — 0 0 — —
Pacific — 0 1 1 3 — 0 0 — 2 — 0 1 — —
Alaska — 0 0 — — — 0 0 — — — 0 0 — —
California — 0 1 1 3 — 0 0 — 2 — 0 1 — —
Hawaii — 0 0 — — — 0 0 — — — 0 0 — —
Oregon — 0 0 — — — 0 0 — — — 0 0 — —
Washington — 0 0 — — — 0 0 — — — 0 0 — —
Territories
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 0 0 — — — 0 0 — — — 0 0 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Case counts for reporting year 2010 are provisional and subject to change.  For further information on interpretation of these data, see http://www.cdc.gov/ncphi/disss/nndss/phs/files/
ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf.  Data for HIV/AIDS, AIDS and TB, when available, are displayed in Table IV, which appears quarterly.
† Cumulative total E. ewingii cases reported for year 2010 = 10.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending November 20, 2010, and November 21, 2009 (46th week)*
Reporting area
Giardiasis Gonorrhea
Haemophilus influenzae, invasive†  
All ages, all serotypes
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 206 348 666 15,828 16,909 2,101 5,519 6,403 247,293 270,108 35 59 171 2,535 2,516
New England 15 32 54 1,436 1,597 71 102 196 4,688 4,434 — 3 21 161 174
Connecticut — 5 13 236 263 — 42 169 1,983 2,142 — 0 15 34 48
Maine§ 4 4 12 203 193 — 3 11 136 121 — 0 2 11 18
Massachusetts 10 13 24 637 690 64 46 81 2,120 1,735 — 2 8 86 82
New Hampshire — 3 8 129 186 3 3 7 140 95 — 0 2 11 12
Rhode Island§ — 1 7 60 60 4 5 14 262 297 — 0 2 11 9
Vermont§ 1 4 10 171 205 — 0 17 47 44 — 0 1 8 5
Mid. Atlantic 44 61 103 2,752 3,095 361 683 1,121 31,774 28,231 11 11 34 505 509
New Jersey — 4 13 208 389 — 106 161 4,814 4,289 — 2 7 78 112
New York (Upstate) 32 22 84 1,049 1,182 191 103 422 5,138 5,210 5 3 20 138 134
New York City 4 17 33 809 752 — 228 529 10,524 9,837 — 2 6 97 62
Pennsylvania 8 15 27 686 772 170 248 365 11,298 8,895 6 4 9 192 201
E.N. Central 19 54 81 2,542 2,639 285 921 1,260 42,179 56,851 2 10 20 428 393
Illinois — 12 26 515 560 — 180 380 7,625 18,101 — 3 9 136 147
Indiana — 5 13 197 271 — 98 221 4,690 6,299 — 1 6 72 70
Michigan 3 13 25 612 604 203 249 471 11,836 13,371 — 0 4 28 23
Ohio 16 17 29 772 732 42 316 375 13,829 14,400 2 2 6 105 87
Wisconsin — 8 30 446 472 40 93 155 4,199 4,680 — 2 5 87 66
W.N. Central 7 25 165 1,278 1,508 124 278 357 12,479 13,333 2 3 24 144 145
Iowa — 5 11 259 269 — 32 53 1,480 1,511 — 0 1 1 —
Kansas — 4 10 192 144 6 39 83 1,749 2,277 — 0 2 15 13
Minnesota — 0 135 136 343 — 38 62 1,629 2,087 — 0 17 25 50
Missouri 7 8 26 392 468 118 136 175 6,208 5,814 1 1 6 72 55
Nebraska§ — 4 9 193 159 — 20 50 938 1,220 1 0 2 21 21
North Dakota — 0 7 28 24 — 2 11 97 120 — 0 4 10 6
South Dakota — 1 7 78 101 — 7 19 378 304 — 0 0 — —
S. Atlantic 65 72 143 3,301 3,321 543 1,346 1,745 61,315 67,401 15 14 27 665 687
Delaware — 0 5 28 23 10 18 48 877 860 — 0 1 5 3
District of Columbia — 1 5 33 68 23 35 66 1,618 2,370 — 0 1 4 5
Florida 50 39 87 1,915 1,738 166 390 493 17,847 18,906 4 3 9 163 202
Georgia — 10 51 485 663 96 207 421 8,674 12,349 5 3 9 156 135
Maryland§ 8 5 11 240 255 126 133 237 6,007 5,491 1 1 6 59 80
North Carolina N 0 0 N N — 246 596 11,923 12,562 5 2 9 113 89
South Carolina§ 1 2 9 124 100 — 152 232 7,112 7,575 — 2 7 71 67
Virginia§ 6 9 36 437 425 122 153 271 6,767 6,845 — 2 4 72 79
West Virginia — 0 6 39 49 — 10 24 490 443 — 0 5 22 27
E.S. Central 1 6 15 241 374 54 475 698 20,972 24,161 1 3 12 150 147
Alabama§ 1 4 11 184 180 — 145 218 6,461 6,814 — 0 3 22 35
Kentucky N 0 0 N N — 73 142 3,333 3,514 — 0 2 30 19
Mississippi N 0 0 N N — 110 216 4,786 6,651 — 0 2 11 8
Tennessee§ — 1 9 57 194 54 147 195 6,392 7,182 1 2 10 87 85
W.S. Central — 8 16 339 469 204 801 1,284 37,556 42,232 2 2 20 113 111
Arkansas§ — 2 7 121 140 74 76 133 3,335 4,033 — 0 3 15 18
Louisiana — 3 9 155 184 — 71 441 3,693 8,060 — 0 3 22 20
Oklahoma — 2 7 63 145 130 78 359 3,962 4,046 2 1 15 68 69
Texas§ N 0 0 N N — 578 964 26,566 26,093 — 0 2 8 4
Mountain 13 30 50 1,466 1,514 70 173 262 7,719 8,336 1 5 15 257 217
Arizona 2 3 8 144 189 39 58 109 2,549 2,800 — 2 10 94 67
Colorado 7 13 27 639 456 — 52 95 2,305 2,524 — 1 5 73 62
Idaho§ 3 4 9 188 188 — 2 6 100 96 1 0 2 17 4
Montana§ 1 2 7 93 124 — 2 6 93 72 — 0 1 2 1
Nevada§ — 1 11 88 102 4 29 94 1,441 1,525 — 0 2 7 18
New Mexico§ — 2 5 83 109 27 19 41 932 955 — 1 5 37 31
Utah — 4 11 195 285 — 6 15 270 299 — 0 4 21 31
Wyoming§ — 1 5 36 61 — 0 4 29 65 — 0 2 6 3
Pacific 42 53 133 2,473 2,392 389 606 816 28,611 25,129 1 2 21 112 133
Alaska — 2 6 86 104 5 24 37 1,092 876 — 0 2 20 20
California 25 33 61 1,536 1,545 333 494 691 23,506 20,653 1 0 18 21 40
Hawaii — 0 3 28 19 — 14 24 651 574 — 0 2 8 28
Oregon — 9 20 424 371 10 19 43 899 982 — 1 5 57 42
Washington 17 8 75 399 353 41 53 80 2,463 2,044 — 0 4 6 3
Territories
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 1 2 3 — 0 4 30 19 — 0 0 — —
Puerto Rico — 1 8 63 145 2 6 14 273 213 — 0 1 1 4
U.S. Virgin Islands — 0 0 — — — 1 7 78 112 — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Case counts for reporting year 2010 are provisional and subject to change.  For further information on interpretation of these data, see http://www.cdc.gov/ncphi/disss/nndss/phs/files/
ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf.  Data for HIV/AIDS, AIDS and TB, when available, are displayed in Table IV, which appears quarterly.
† Data for H. influenzae (age <5 yrs for serotype b, nonserotype b, and unknown serotype) are available in Table I.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
MMWR  Morbidity and Mortality Weekly Report
 MMWR  /  November 26, 2010  /  Vol. 59  /  No. 46 1531 
TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending November 20, 2010, and November 21, 2009 (46th week)*

















Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 20 31 69 1,363 1,764 27 62 204 2,741 2,900 11 14 44 716 665
New England — 2 5 86 100 — 1 5 47 49 1 1 4 37 60
Connecticut — 0 3 28 18 — 0 2 18 15 — 0 4 25 47
Maine† — 0 1 7 1 — 0 2 13 13 — 0 0 — 2
Massachusetts — 1 5 41 64 — 0 2 8 17 — 0 1 10 10
New Hampshire — 0 1 2 7 — 0 2 6 4 N 0 0 N N
Rhode Island† — 0 4 8 8 U 0 0 U U U 0 0 U U
Vermont† — 0 0 — 2 — 0 1 2 — 1 0 1 2 1
Mid. Atlantic 2 4 10 185 247 3 5 10 246 301 3 2 6 98 91
New Jersey — 0 3 12 61 — 1 5 57 91 — 0 2 14 6
New York (Upstate) 1 1 4 54 43 3 1 6 48 47 3 1 4 55 42
New York City — 1 5 68 81 — 2 4 75 63 — 0 1 1 5
Pennsylvania 1 1 4 51 62 — 1 5 66 100 — 0 3 28 38
E.N. Central — 4 9 193 265 — 9 17 403 392 — 2 8 102 81
Illinois — 1 3 44 121 — 1 5 77 109 — 0 1 2 4
Indiana — 0 2 15 16 — 1 5 47 67 — 0 2 21 19
Michigan — 1 4 64 64 — 3 6 109 115 — 1 4 63 29
Ohio — 0 5 44 35 — 2 6 84 80 — 0 1 8 26
Wisconsin — 0 3 26 29 — 1 8 86 21 — 0 2 8 3
W.N. Central — 1 13 69 111 — 2 15 108 124 — 0 11 22 21
Iowa — 0 3 9 35 — 0 2 13 31 — 0 1 — 10
Kansas — 0 3 11 12 — 0 2 8 6 — 0 1 2 1
Minnesota — 0 12 15 19 — 0 13 8 24 — 0 9 12 6
Missouri — 0 2 21 21 — 1 3 66 41 — 0 1 6 —
Nebraska† — 0 4 12 20 — 0 2 12 19 — 0 1 2 2
North Dakota — 0 1 — 1 — 0 0 — — — 0 1 — 1
South Dakota — 0 1 1 3 — 0 1 1 3 — 0 0 — 1
S. Atlantic 6 7 14 310 386 11 16 40 786 797 4 4 7 155 151
Delaware — 0 1 7 3 — 0 2 23 30 U 0 0 U U
District of Columbia — 0 1 1 1 — 0 1 3 10 — 0 1 2 1
Florida 4 3 7 126 158 7 6 11 269 258 2 1 5 52 44
Georgia — 1 3 35 47 2 3 7 134 134 — 0 2 8 30
Maryland† 1 0 3 21 44 1 1 6 68 68 1 0 2 24 21
North Carolina — 1 5 45 36 1 1 16 89 98 1 0 3 39 21
South Carolina† — 0 3 22 56 — 1 4 51 52 — 0 1 1 1
Virginia† 1 1 6 46 36 — 2 14 88 86 — 0 2 12 8
West Virginia — 0 5 7 5 — 0 14 61 61 — 0 5 17 25
E.S. Central 1 1 3 37 37 — 7 13 322 307 3 3 8 133 92
Alabama† — 0 1 6 10 — 1 4 61 80 — 0 1 6 7
Kentucky 1 0 3 17 9 — 2 8 114 80 1 2 5 90 55
Mississippi — 0 1 2 8 — 1 3 35 29 U 0 0 U U
Tennessee† — 0 2 12 10 — 2 8 112 118 2 1 4 37 30
W.S. Central 2 3 19 126 173 7 9 109 436 511 — 1 14 65 53
Arkansas† — 0 1 2 11 — 0 4 41 60 — 0 0 — 2
Louisiana — 0 2 10 6 — 1 4 42 64 — 0 1 7 7
Oklahoma — 0 3 1 3 3 2 19 85 90 — 0 12 28 12
Texas† 2 2 18 113 153 4 5 87 268 297 — 0 3 30 32
Mountain — 3 8 132 145 — 2 8 121 118 — 1 5 48 48
Arizona — 1 5 59 60 — 0 2 28 39 U 0 0 U U
Colorado — 1 3 34 47 — 1 5 40 23 — 0 1 12 26
Idaho† — 0 2 6 4 — 0 1 6 11 — 0 2 9 6
Montana† — 0 1 4 6 — 0 1 1 1 — 0 1 2 1
Nevada† — 0 2 14 13 — 1 3 35 29 — 0 1 4 4
New Mexico† — 0 1 4 8 — 0 1 5 6 — 0 2 11 6
Utah — 0 1 8 5 — 0 1 5 5 — 0 2 10 5
Wyoming† — 0 3 3 2 — 0 1 1 4 — 0 0 — —
Pacific 9 5 16 225 300 6 6 20 272 301 — 1 6 56 68
Alaska — 0 1 2 2 — 0 1 3 3 U 0 0 U U
California 9 4 16 187 238 5 4 17 190 212 — 0 4 22 37
Hawaii — 0 2 3 8 — 0 1 2 6 U 0 0 U U
Oregon — 0 2 16 15 — 1 3 34 40 — 0 3 15 17
Washington — 0 2 17 37 1 1 4 43 40 — 0 6 19 14
Territories
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 6 18 6 — 1 6 40 54 — 0 7 35 48
Puerto Rico — 0 2 13 21 — 0 2 17 31 — 0 0 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Case counts for reporting year 2010 are provisional and subject to change.  For further information on interpretation of these data, see http://www.cdc.gov/ncphi/disss/nndss/phs/files/
ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf.  Data for HIV/AIDS, AIDS and TB, when available, are displayed in Table IV, which appears quarterly.
† Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending November 20, 2010, and November 21, 2009 (46th week)*
Reporting area
Legionellosis Lyme disease Malaria
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 51 57 114 2,863 3,160 106 396 2,336 24,718 34,479 11 27 89 1,314 1,245
New England — 3 15 211 185 9 123 474 7,215 11,838 — 2 4 65 55
Connecticut — 1 6 43 50 — 36 200 2,257 4,002 — 0 1 1 5
Maine† — 0 4 12 8 8 11 76 649 835 — 0 1 5 2
Massachusetts — 1 8 103 88 1 41 206 2,763 5,053 — 1 3 45 36
New Hampshire — 0 5 21 13 — 22 67 1,093 1,338 — 0 2 4 4
Rhode Island† — 0 4 23 19 — 1 40 147 224 — 0 1 7 5
Vermont† — 0 2 9 7 — 4 27 306 386 — 0 1 3 3
Mid. Atlantic 7 15 38 775 1,104 57 168 721 11,431 15,022 1 7 17 359 370
New Jersey — 2 11 93 205 — 41 207 2,918 4,810 — 0 4 1 92
New York (Upstate) 2 5 19 257 323 33 51 577 2,676 3,718 1 1 6 68 43
New York City — 2 10 131 215 — 2 14 67 995 — 4 14 235 185
Pennsylvania 5 5 18 294 361 24 77 383 5,770 5,499 — 1 3 55 50
E.N. Central 9 11 41 640 672 1 15 260 2,123 2,861 — 2 9 132 157
Illinois — 1 15 120 121 — 1 16 115 136 — 1 7 47 65
Indiana 1 2 6 100 60 — 1 7 66 81 — 0 2 8 21
Michigan — 2 20 161 155 — 1 13 90 98 — 0 4 29 28
Ohio 8 4 15 213 264 — 0 5 22 50 — 0 5 38 34
Wisconsin — 0 11 46 72 1 12 235 1,830 2,496 — 0 1 10 9
W.N. Central 8 2 19 115 109 — 2 1,395 113 229 — 1 11 64 63
Iowa — 0 2 13 22 — 0 10 78 106 — 0 2 12 10
Kansas — 0 2 11 7 — 0 1 6 18 — 0 2 10 8
Minnesota 8 0 16 35 12 — 0 1,380 — 96 — 0 11 3 24
Missouri — 0 4 33 53 — 0 1 1 3 — 0 3 21 12
Nebraska† — 0 2 9 12 — 0 2 9 5 — 0 2 15 8
North Dakota — 0 1 6 1 — 0 15 18 — — 0 1 — —
South Dakota — 0 2 8 2 — 0 1 1 1 — 0 2 3 1
S. Atlantic 20 10 27 482 535 35 58 175 3,477 4,077 7 7 42 377 322
Delaware — 0 3 15 19 — 10 32 565 932 — 0 1 2 5
District of Columbia — 0 4 15 21 — 0 4 25 61 — 0 2 9 17
Florida 6 3 9 152 167 2 1 10 92 100 3 2 7 116 83
Georgia 1 1 4 48 55 — 0 2 11 38 — 0 5 41 65
Maryland† 5 2 6 104 139 7 25 100 1,513 1,919 — 1 22 91 62
North Carolina 2 0 7 53 58 — 1 9 80 93 2 0 13 47 29
South Carolina† — 0 2 10 11 — 0 3 28 37 — 0 1 4 5
Virginia† 6 1 6 72 56 26 17 79 1,045 733 2 1 5 64 54
West Virginia — 0 3 13 9 — 0 32 118 164 — 0 2 3 2
E.S. Central 1 2 10 119 129 — 1 4 43 35 — 0 3 29 30
Alabama† — 0 2 17 17 — 0 1 2 3 — 0 1 9 9
Kentucky — 0 4 26 47 — 0 1 5 1 — 0 3 6 9
Mississippi — 0 3 9 4 — 0 0 — — — 0 2 2 3
Tennessee† 1 1 6 67 61 — 1 4 36 31 — 0 2 12 9
W.S. Central 1 3 14 134 116 1 2 44 94 210 1 1 31 76 63
Arkansas† 1 0 2 14 7 — 0 0 — — — 0 1 2 5
Louisiana — 0 3 8 13 — 0 1 2 — — 0 1 4 5
Oklahoma — 0 4 13 6 — 0 2 — — — 0 1 5 1
Texas† — 2 10 99 90 1 2 42 92 210 1 1 30 65 52
Mountain 1 3 10 152 133 — 0 3 23 53 — 1 4 57 46
Arizona 1 1 6 59 42 — 0 1 2 6 — 0 2 22 9
Colorado — 1 5 32 27 — 0 1 3 1 — 0 3 20 26
Idaho† — 0 1 6 6 — 0 2 7 15 — 0 1 3 2
Montana† — 0 1 4 7 — 0 1 3 3 — 0 1 2 5
Nevada† — 0 2 19 12 — 0 1 1 12 — 0 1 6 —
New Mexico† — 0 2 7 9 — 0 2 5 5 — 0 1 1 —
Utah — 0 2 20 26 — 0 1 2 9 — 0 1 3 4
Wyoming† — 0 2 5 4 — 0 1 — 2 — 0 0 — —
Pacific 4 5 19 235 177 3 4 11 199 154 2 3 19 155 139
Alaska — 0 2 2 1 — 0 1 6 6 — 0 1 3 2
California 4 4 19 197 136 3 3 9 132 97 1 2 13 106 104
Hawaii — 0 1 1 1 N 0 0 N N — 0 1 1 1
Oregon — 0 3 12 16 — 1 4 48 37 — 0 3 12 11
Washington — 0 4 23 23 — 0 3 13 14 1 0 5 33 21
Territories
American Samoa — 0 0 — — N 0 0 N N — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 1 1 — — 0 0 — — — 0 0 — —
Puerto Rico — 0 1 — 2 N 0 0 N N — 0 2 4 5
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Case counts for reporting year 2010 are provisional and subject to change.  For further information on interpretation of these data, see http://www.cdc.gov/ncphi/disss/nndss/phs/files/
ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf.  Data for HIV/AIDS, AIDS and TB, when available, are displayed in Table IV, which appears quarterly.
† Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending November 20, 2010, and November 21, 2009 (46th week)*
Reporting area
Meningococcal disease, invasive† 
All groups Pertussis Rabies, animal
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 12 15 43 666 837 241 331 1,756 17,250 13,750 28 64 140 2,931 4,716
New England 1 0 3 17 30 4 8 23 434 582 1 4 15 210 313
Connecticut — 0 2 2 4 — 1 8 95 50 — 0 14 59 132
Maine§ 1 0 1 4 4 1 0 5 43 77 1 1 4 58 50
Massachusetts — 0 2 6 14 2 5 14 239 331 — 0 0 — —
New Hampshire — 0 0 — 3 — 0 2 18 72 — 0 5 13 31
Rhode Island§ — 0 0 — 4 — 0 9 26 41 — 1 4 31 41
Vermont§ — 0 1 5 1 1 0 4 13 11 — 1 5 49 59
Mid. Atlantic — 1 4 62 95 53 26 63 1,396 1,073 7 18 41 893 522
New Jersey — 0 2 16 17 — 2 8 109 221 — 0 0 — —
New York (Upstate) — 0 3 11 20 18 9 27 485 203 7 9 19 463 404
New York City — 0 2 14 16 — 0 9 78 86 — 2 12 120 18
Pennsylvania — 0 2 21 42 35 11 42 724 563 — 5 24 310 100
E.N. Central 2 2 8 114 153 79 82 173 4,350 2,834 — 2 27 222 217
Illinois — 0 3 19 41 — 14 29 711 578 — 1 11 114 82
Indiana — 0 3 23 33 — 9 26 470 339 — 0 0 — 25
Michigan — 0 3 20 19 12 26 54 1,233 778 — 1 5 64 64
Ohio 2 1 2 31 39 66 27 71 1,527 983 — 0 12 44 46
Wisconsin — 0 2 21 21 1 7 20 409 156 — 0 0 — —
W.N. Central — 1 6 43 71 22 32 627 2,007 2,008 1 4 16 220 361
Iowa — 0 3 9 11 — 9 26 451 216 — 0 2 7 31
Kansas — 0 2 6 13 — 3 9 142 226 — 1 4 58 72
Minnesota — 0 2 2 11 — 0 601 698 421 — 0 9 26 60
Missouri — 0 3 19 22 20 8 39 439 942 — 1 6 65 64
Nebraska§ — 0 2 5 9 2 4 13 201 132 1 1 4 49 77
North Dakota — 0 1 2 1 — 0 30 50 29 — 0 7 15 4
South Dakota — 0 1 — 4 — 0 5 26 42 — 0 2 — 53
S. Atlantic 2 2 7 121 153 16 28 78 1,359 1,489 18 21 73 986 1,964
Delaware — 0 1 2 2 — 0 4 12 13 — 0 0 — —
District of Columbia — 0 0 — — — 0 1 6 6 — 0 0 — —
Florida 1 1 5 55 49 7 5 28 287 477 — 0 60 72 161
Georgia — 0 2 10 30 1 3 18 213 212 — 0 13 — 375
Maryland§ — 0 1 8 10 1 3 8 120 135 5 6 14 337 363
North Carolina 1 0 2 15 29 — 0 32 124 186 — 0 7 — 440
South Carolina§ — 0 1 10 11 1 5 19 298 239 — 0 0 — —
Virginia§ — 0 2 19 16 6 5 15 214 191 13 10 25 506 514
West Virginia — 0 2 2 6 — 1 13 85 30 — 1 7 71 111
E.S. Central — 1 3 38 30 2 14 34 668 727 — 3 7 137 134
Alabama§ — 0 2 6 8 — 4 8 176 282 — 1 4 49 —
Kentucky — 0 2 17 5 — 5 14 231 210 — 0 4 19 45
Mississippi — 0 1 5 3 — 1 8 63 66 — 0 1 1 4
Tennessee§ — 0 2 10 14 2 4 11 198 169 — 1 4 68 85
W.S. Central 3 1 9 78 82 26 56 753 2,523 2,950 — 0 30 61 864
Arkansas§ — 0 1 6 9 — 3 29 159 317 — 0 7 21 38
Louisiana — 0 4 12 17 — 1 4 32 143 — 0 0 — —
Oklahoma — 0 7 15 12 2 0 41 65 73 — 0 30 40 32
Texas§ 3 1 7 45 44 24 48 681 2,267 2,417 — 0 14 — 794
Mountain 1 1 6 52 57 33 24 57 1,311 875 — 1 8 77 102
Arizona — 0 2 13 12 4 7 16 367 231 — 0 5 — —
Colorado 1 0 4 19 19 29 4 40 320 204 — 0 0 — —
Idaho§ — 0 2 7 7 — 3 19 180 69 — 0 2 11 8
Montana§ — 0 1 1 5 — 1 12 75 54 — 0 3 16 25
Nevada§ — 0 1 8 4 — 0 7 31 24 — 0 2 8 6
New Mexico§ — 0 1 3 3 — 2 11 119 66 — 0 2 11 26
Utah — 0 1 1 2 — 4 13 209 205 — 0 2 10 13
Wyoming§ — 0 0 — 5 — 0 2 10 22 — 0 4 21 24
Pacific 3 3 16 141 166 6 40 209 3,202 1,212 1 3 12 125 239
Alaska — 0 1 1 6 — 0 6 37 50 — 0 2 12 12
California 3 2 13 94 105 2 27 181 2,438 630 1 2 12 101 216
Hawaii — 0 1 1 5 — 0 6 41 41 — 0 0 — —
Oregon — 1 2 29 37 — 6 16 294 240 — 0 2 12 11
Washington — 0 7 16 13 4 5 38 392 251 — 0 0 — —
Territories
American Samoa — 0 0 — — — 0 0 — — N 0 0 N N
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 2 — 2 — 0 0 — —
Puerto Rico — 0 1 — 1 — 0 1 3 1 — 1 3 40 39
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Case counts for reporting year 2010 are provisional and subject to change.  For further information on interpretation of these data, see http://www.cdc.gov/ncphi/disss/nndss/phs/files/
ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf.  Data for HIV/AIDS, AIDS and TB, when available, are displayed in Table IV, which appears quarterly.
† Data for meningococcal disease, invasive caused by serogroups A, C, Y, and W-135; serogroup B; other serogroup; and unknown serogroup are available in Table I.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending November 20, 2010, and November 21, 2009 (46th week)*
Reporting area
Salmonellosis Shiga toxin-producing E. coli (STEC)† Shigellosis
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 668 900 1,706 45,573 43,732 56 84 208 4,250 4,176 193 273 527 12,195 13,935
New England 5 32 448 2,076 2,009 1 3 52 186 283 1 4 62 290 318
Connecticut — 0 432 432 430 — 0 52 52 67 — 0 57 57 43
Maine§ 1 2 7 117 114 — 0 3 18 19 1 0 1 7 5
Massachusetts 3 23 54 1,164 1,032 — 2 8 77 99 — 4 16 202 221
New Hampshire — 3 10 152 242 — 0 2 20 35 — 0 1 12 21
Rhode Island§ — 2 17 140 131 — 0 26 2 38 — 0 3 11 23
Vermont§ 1 1 5 71 60 1 0 2 17 25 — 0 1 1 5
Mid. Atlantic 48 94 219 5,212 4,997 3 9 31 459 392 5 33 53 1,410 2,563
New Jersey — 19 57 977 1,035 — 1 6 56 97 — 6 16 288 556
New York (Upstate) 25 25 78 1,306 1,174 3 3 13 179 135 — 4 19 207 195
New York City 7 25 56 1,242 1,164 — 1 7 67 55 1 6 14 271 418
Pennsylvania 16 29 82 1,687 1,624 — 3 13 157 105 4 14 34 644 1,394
E.N. Central 19 86 239 4,706 4,734 4 10 39 673 667 9 26 238 1,517 2,322
Illinois — 28 114 1,636 1,345 — 2 9 115 157 — 9 228 741 555
Indiana — 9 55 430 566 — 1 9 66 89 — 1 5 33 63
Michigan 4 15 48 844 891 — 2 16 149 127 — 5 9 218 209
Ohio 15 24 47 1,204 1,307 4 2 11 133 121 9 6 23 284 1,025
Wisconsin — 11 44 592 625 — 3 17 210 173 — 4 21 241 470
W.N. Central 24 45 98 2,224 2,411 2 12 39 602 681 6 48 88 1,895 1,040
Iowa — 9 34 479 370 — 3 16 162 150 — 1 5 48 49
Kansas — 8 19 404 364 — 1 6 64 53 — 5 14 238 185
Minnesota — 0 32 178 512 — 0 13 31 195 — 0 3 14 73
Missouri 15 13 44 752 597 2 4 27 226 128 6 42 75 1,533 696
Nebraska§ 9 4 13 235 324 — 1 6 70 81 — 1 10 55 29
North Dakota — 0 39 48 63 — 0 10 17 8 — 0 5 — 4
South Dakota — 3 8 128 181 — 0 4 32 66 — 0 2 7 4
S. Atlantic 422 268 601 14,127 12,838 18 13 30 659 619 85 45 97 2,326 2,156
Delaware — 3 11 164 129 — 0 2 6 13 — 1 8 39 134
District of Columbia — 1 6 66 92 — 0 1 5 2 — 0 4 23 22
Florida 164 121 227 5,686 5,822 4 4 13 218 159 34 14 53 1,010 421
Georgia 39 41 132 2,520 2,178 — 1 15 100 67 11 13 39 693 593
Maryland§ 16 15 54 941 725 4 1 8 91 87 3 2 8 119 348
North Carolina 183 29 197 2,145 1,677 9 1 10 82 101 35 3 18 216 343
South Carolina§ 6 20 94 1,431 1,051 — 0 3 19 30 — 1 5 61 112
Virginia§ 14 18 68 1,016 966 1 2 15 120 131 2 2 15 129 175
West Virginia — 2 16 158 198 — 0 4 18 29 — 0 11 36 8
E.S. Central 27 52 177 3,593 2,848 2 5 19 246 197 4 13 40 660 743
Alabama§ 9 18 51 937 855 — 1 4 46 44 1 3 13 168 145
Kentucky 7 10 31 528 415 — 1 6 65 66 1 3 28 210 200
Mississippi — 16 67 1,146 854 1 0 12 28 6 — 1 4 48 44
Tennessee§ 11 14 53 982 724 1 2 7 107 81 2 5 14 234 354
W.S. Central 23 98 547 5,412 5,381 6 5 68 271 289 54 51 251 2,344 2,609
Arkansas§ 3 11 43 722 569 — 1 5 45 41 1 1 9 65 285
Louisiana — 19 48 1,099 1,106 — 0 2 17 23 — 5 13 232 166
Oklahoma 12 11 46 615 571 6 0 27 40 31 7 6 96 247 256
Texas§ 8 51 477 2,976 3,135 — 3 41 169 194 46 38 144 1,800 1,902
Mountain 15 48 105 2,490 2,768 4 10 34 573 534 4 15 32 713 1,060
Arizona 2 18 42 861 978 1 1 9 78 64 3 8 19 396 763
Colorado 9 10 24 529 570 — 3 21 208 160 1 2 6 91 90
Idaho§ 4 3 9 148 159 3 1 7 94 88 — 0 3 23 8
Montana§ — 2 7 81 101 — 1 5 39 34 — 0 1 6 11
Nevada§ — 4 22 266 233 — 0 5 28 34 — 1 6 44 66
New Mexico§ — 5 16 288 339 — 1 5 35 34 — 2 9 114 100
Utah — 5 17 278 298 — 1 7 76 106 — 1 4 39 18
Wyoming§ — 1 5 39 90 — 0 2 15 14 — 0 0 — 4
Pacific 85 124 299 5,733 5,746 16 10 46 581 514 25 21 64 1,040 1,124
Alaska — 1 5 75 63 — 0 1 2 1 — 0 2 1 2
California 52 89 227 4,339 4,292 15 6 35 266 237 23 16 51 863 902
Hawaii 2 4 14 197 302 — 0 4 18 11 — 0 3 19 38
Oregon — 8 48 459 396 — 2 9 100 77 — 1 4 55 49
Washington 31 15 61 663 693 1 3 19 195 188 2 2 20 102 133
Territories
American Samoa — 0 1 2 — — 0 0 — — — 1 1 4 3
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 2 7 11 — 0 0 — — — 0 1 1 13
Puerto Rico — 11 39 456 502 — 0 0 — — — 0 1 4 13
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Case counts for reporting year 2010 are provisional and subject to change.  For further information on interpretation of these data, see http://www.cdc.gov/ncphi/disss/nndss/phs/files/
ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf.  Data for HIV/AIDS, AIDS and TB, when available, are displayed in Table IV, which appears quarterly.
† Includes E. coli O157:H7; Shiga toxin-positive, serogroup non-O157; and Shiga toxin-positive, not serogrouped.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
MMWR  Morbidity and Mortality Weekly Report
 MMWR  /  November 26, 2010  /  Vol. 59  /  No. 46 1535 
TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending November 20, 2010, and November 21, 2009 (46th week)*











Previous 52 weeks Cum  
2010
Cum  
2009Med Max Med Max
United States 1 2 12 150 141 30 19 421 1,412 1,212
New England — 0 0 — 2 — 0 1 3 10
Connecticut — 0 0 — — — 0 0 — —
Maine§ — 0 0 — — — 0 1 2 5
Massachusetts — 0 0 — 1 — 0 1 — 5
New Hampshire — 0 0 — — — 0 1 1 —
Rhode Island§ — 0 0 — — — 0 0 — —
Vermont§ — 0 0 — 1 — 0 0 — —
Mid. Atlantic — 0 2 16 12 — 1 4 57 92
New Jersey — 0 0 — 2 — 0 2 — 58
New York (Upstate) — 0 1 2 — — 0 3 17 14
New York City — 0 1 1 1 — 0 4 27 7
Pennsylvania — 0 2 13 9 — 0 1 13 13
E.N. Central — 0 1 4 9 — 1 9 91 81
Illinois — 0 1 2 1 — 0 5 33 48
Indiana — 0 1 2 3 — 0 5 43 10
Michigan — 0 0 — 4 — 0 1 1 1
Ohio — 0 0 — — — 0 2 13 18
Wisconsin — 0 0 — 1 — 0 1 1 4
W.N. Central — 0 4 17 18 — 4 21 301 250
Iowa — 0 0 — 1 — 0 1 4 4
Kansas — 0 1 2 1 — 0 0 — —
Minnesota — 0 1 — 1 — 0 1 — 1
Missouri — 0 4 13 7 — 4 20 293 241
Nebraska§ — 0 1 2 8 — 0 1 3 4
North Dakota — 0 0 — — — 0 1 1 —
South Dakota — 0 0 — — — 0 0 — —
S. Atlantic 1 1 9 78 65 12 7 60 482 368
Delaware — 0 1 1 — — 0 3 19 17
District of Columbia — 0 1 1 — — 0 1 — —
Florida 1 0 1 4 — 1 0 2 11 7
Georgia — 0 6 53 51 — 0 0 — —
Maryland§ — 0 1 3 3 1 1 4 52 36
North Carolina — 0 3 11 7 7 1 48 251 241
South Carolina§ — 0 1 1 3 — 0 2 18 15
Virginia§ — 0 2 4 1 3 2 12 131 50
West Virginia — 0 0 — — — 0 0 — 2
E.S. Central — 0 3 19 9 2 5 29 370 252
Alabama§ — 0 1 5 3 — 1 8 73 61
Kentucky — 0 2 6 1 — 0 0 — —
Mississippi — 0 0 — — — 0 2 12 9
Tennessee§ — 0 2 8 5 2 4 20 285 182
W.S. Central — 0 3 6 9 16 1 408 96 135
Arkansas§ — 0 2 2 — 13 0 110 50 68
Louisiana — 0 0 — — — 0 1 2 2
Oklahoma — 0 3 3 7 3 0 287 25 46
Texas§ — 0 1 1 2 — 0 11 19 19
Mountain — 0 1 2 16 — 0 2 12 24
Arizona — 0 1 — 10 — 0 1 2 12
Colorado — 0 0 — 1 — 0 1 1 —
Idaho§ — 0 0 — — — 0 1 5 1
Montana§ — 0 1 2 4 — 0 1 1 6
Nevada§ — 0 0 — — — 0 0 — 1
New Mexico§ — 0 0 — — — 0 1 1 1
Utah — 0 0 — — — 0 1 1 1
Wyoming§ — 0 0 — 1 — 0 1 1 2
Pacific — 0 2 8 1 — 0 0 — —
Alaska N 0 0 N N N 0 0 N N
California — 0 2 7 1 — 0 0 — —
Hawaii N 0 0 N N N 0 0 N N
Oregon — 0 1 1 — — 0 0 — —
Washington — 0 0 — — — 0 0 — —
Territories
American Samoa N 0 0 N N N 0 0 N N
C.N.M.I. — — — — — — — — — —
Guam N 0 0 N N N 0 0 N N
Puerto Rico N 0 0 N N N 0 0 N N
U.S. Virgin Islands — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Case counts for reporting year 2010 are provisional and subject to change.  For further information on interpretation of these data, see http://www.cdc.gov/ncphi/disss/nndss/phs/files/
ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf.  Data for HIV/AIDS, AIDS and TB, when available, are displayed in Table IV, which appears quarterly.
† Illnesses with similar clinical presentation that result from Spotted fever group rickettsia infections are reported as Spotted fever rickettsioses. Rocky Mountain spotted fever (RMSF) caused 
by Rickettsia rickettsii, is the most common and well-known spotted fever.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending November 20, 2010, and November 21, 2009 (46th week)*
Streptococcus pneumoniae,† invasive disease
Reporting area
All ages Age <5 Syphilis, primary and secondary
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 207 224 495 12,349 2,603 20 45 156 1,906 2,106 53 242 413 10,871 12,475
New England 4 9 99 650 46 1 1 24 87 69 6 9 22 408 288
Connecticut — 0 91 288 — — 0 22 27 — — 1 10 81 51
Maine§ 2 2 6 107 16 1 0 1 9 8 — 0 3 23 3
Massachusetts — 1 5 58 3 — 1 4 40 42 2 5 15 245 207
New Hampshire — 0 7 59 — — 0 1 3 11 — 0 2 22 13
Rhode Island§ — 0 36 69 15 — 0 3 3 4 4 0 4 35 14
Vermont§ 2 1 6 69 12 — 0 1 5 4 — 0 2 2 —
Mid. Atlantic 7 24 56 1,182 180 1 7 48 315 268 9 33 45 1,495 1,581
New Jersey — 1 8 91 — — 1 5 48 55 — 4 12 203 205
New York (Upstate) — 3 12 137 75 — 2 19 99 120 3 2 11 118 106
New York City 1 8 31 517 15 1 2 24 115 78 — 19 31 838 958
Pennsylvania 6 8 22 437 90 — 1 5 53 15 6 7 16 336 312
E.N. Central 39 47 98 2,502 586 — 7 18 315 355 1 26 47 1,163 1,387
Illinois — 1 7 88 — — 2 5 81 62 — 8 24 378 674
Indiana — 7 24 452 220 — 1 6 39 71 — 3 14 152 139
Michigan 5 11 27 603 25 — 2 6 73 67 — 4 12 187 213
Ohio 28 19 49 1,047 341 — 2 6 89 117 1 9 18 408 320
Wisconsin 6 6 22 312 — — 0 4 33 38 — 1 3 38 41
W.N. Central 11 8 182 655 163 3 2 12 118 165 2 6 19 300 278
Iowa — 0 0 — — — 0 0 — — — 0 3 16 21
Kansas — 1 7 80 52 — 0 2 13 18 — 0 3 18 29
Minnesota — 0 179 287 41 — 0 10 44 78 — 2 9 114 64
Missouri 6 2 10 103 59 2 1 3 37 42 2 3 10 142 155
Nebraska§ 5 2 7 114 2 1 0 2 14 12 — 0 1 6 5
North Dakota — 0 11 55 7 — 0 1 2 5 — 0 0 — 4
South Dakota — 0 3 16 2 — 0 2 8 10 — 0 1 4 —
S. Atlantic 60 50 144 2,835 1,177 6 9 28 470 505 16 57 218 2,671 3,007
Delaware — 0 3 34 18 — 0 0 — 3 — 0 1 4 27
District of Columbia — 0 4 24 19 — 0 2 7 5 1 2 21 145 158
Florida 26 22 89 1,276 679 1 3 18 172 174 1 20 44 959 927
Georgia 12 10 28 483 364 3 3 12 132 146 4 13 167 584 724
Maryland§ 18 7 31 446 4 2 1 6 48 71 4 6 14 276 274
North Carolina — 0 0 — — — 0 0 — — — 7 31 307 512
South Carolina§ 1 6 25 419 — — 1 4 45 45 — 2 7 129 111
Virginia§ — 1 4 49 — — 1 4 47 42 6 4 22 262 270
West Virginia 3 2 21 104 93 — 0 4 19 19 — 0 2 5 4
E.S. Central 20 21 50 1,100 238 1 2 8 109 133 1 17 39 799 1,025
Alabama§ — 0 0 — — — 0 0 — — — 5 11 212 393
Kentucky — 3 16 165 69 — 0 2 13 8 — 2 13 117 62
Mississippi — 1 6 48 48 — 0 2 10 24 — 4 17 193 192
Tennessee§ 20 17 44 887 121 1 2 7 86 101 1 6 17 277 378
W.S. Central 40 26 91 1,601 107 3 5 41 252 314 5 38 62 1,662 2,513
Arkansas§ — 3 9 147 50 — 0 3 16 39 4 3 13 159 251
Louisiana — 2 8 83 57 — 0 3 22 28 — 7 27 366 692
Oklahoma 2 1 5 42 — 2 1 5 42 52 1 2 7 75 83
Texas§ 38 22 83 1,329 — 1 3 34 172 195 — 25 35 1,062 1,487
Mountain 24 28 82 1,567 103 5 4 12 209 268 1 9 23 430 476
Arizona 11 10 51 686 — 2 2 7 87 109 — 3 7 124 213
Colorado 10 9 20 488 — 2 1 4 61 45 — 3 8 118 87
Idaho§ — 0 2 15 — — 0 2 9 8 — 0 1 2 3
Montana§ 1 0 2 20 — 1 0 1 3 — — 0 2 3 3
Nevada§ — 1 4 71 36 — 0 1 5 7 — 1 9 104 86
New Mexico§ 2 2 9 134 — — 0 4 16 34 1 1 4 43 54
Utah — 2 9 142 56 — 0 3 25 63 — 1 4 36 27
Wyoming§ — 0 1 11 11 — 0 1 3 2 — 0 0 — 3
Pacific 2 5 14 257 3 — 0 7 31 29 12 42 61 1,943 1,920
Alaska 1 2 9 100 — — 0 5 19 19 — 0 1 1 —
California 1 3 12 157 — — 0 2 12 — 8 35 54 1,669 1,710
Hawaii — 0 0 — 3 — 0 0 — 10 — 0 3 28 33
Oregon — 0 0 — — — 0 0 — — 1 1 7 57 48
Washington — 0 0 — — — 0 0 — — 3 4 11 188 129
Territories
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 0 0 — — — 0 0 — — 4 3 15 200 196
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Case counts for reporting year 2010 are provisional and subject to change.  For further information on interpretation of these data, see http://www.cdc.gov/ncphi/disss/nndss/phs/files/
ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf.  Data for HIV/AIDS, AIDS and TB, when available, are displayed in Table IV, which appears quarterly.
† Includes drug resistant and susceptible cases of invasive Streptococcus pneumoniae disease among children <5 years and among all ages. Case definition: Isolation of S. pneumoniae from 
a normally sterile body site (e.g., blood or cerebrospinal fluid).
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending November 20, 2010, and November 21, 2009 (46th week)*
West Nile virus disease†
Reporting area
Varicella (chickenpox)§ Neuroinvasive Nonneuroinvasive¶
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 173 282 549 12,586 18,614 — 0 70 585 384 — 0 52 372 334
New England 3 15 36 637 985 — 0 3 13 — — 0 1 2 —
Connecticut — 6 20 256 449 — 0 2 6 — — 0 1 1 —
Maine§ — 3 15 195 216 — 0 0 — — — 0 0 — —
Massachusetts — 0 1 2 4 — 0 2 6 — — 0 1 1 —
New Hampshire — 2 8 114 185 — 0 1 1 — — 0 0 — —
Rhode Island§ — 1 12 32 38 — 0 0 — — — 0 0 — —
Vermont§ 3 0 10 38 93 — 0 0 — — — 0 0 — —
Mid. Atlantic 16 31 62 1,414 1,864 — 0 19 125 9 — 0 13 62 1
New Jersey — 8 30 463 413 — 0 3 15 3 — 0 6 15 —
New York (Upstate) N 0 0 N N — 0 9 57 3 — 0 7 30 1
New York City — 0 0 — — — 0 7 32 3 — 0 4 8 —
Pennsylvania 16 22 39 951 1,451 — 0 3 21 — — 0 3 9 —
E.N. Central 65 100 176 4,250 5,883 — 0 14 73 9 — 0 6 28 4
Illinois 6 23 45 1,074 1,456 — 0 10 41 5 — 0 4 15 —
Indiana§ 2 6 35 367 408 — 0 1 4 2 — 0 2 6 2
Michigan 23 31 62 1,274 1,725 — 0 6 25 1 — 0 1 4 —
Ohio 32 29 56 1,217 1,758 — 0 1 3 — — 0 1 1 2
Wisconsin 2 7 22 318 536 — 0 0 — 1 — 0 1 2 —
W.N. Central 15 16 40 725 1,156 — 0 7 28 26 — 0 11 68 75
Iowa N 0 0 N N — 0 1 2 — — 0 2 4 5
Kansas§ — 4 22 231 504 — 0 1 3 4 — 0 2 10 9
Minnesota — 0 0 — — — 0 1 4 1 — 0 3 4 3
Missouri 15 7 23 413 543 — 0 1 3 4 — 0 0 — 1
Nebraska§ N 0 0 N N — 0 3 10 11 — 0 7 27 41
North Dakota — 0 26 37 57 — 0 2 2 — — 0 2 7 1
South Dakota — 0 7 44 52 — 0 2 4 6 — 0 3 16 15
S. Atlantic 31 34 100 1,909 2,357 — 0 4 32 16 — 0 4 20 2
Delaware§ — 0 3 22 12 — 0 0 — — — 0 0 — —
District of Columbia — 0 4 17 30 — 0 1 1 2 — 0 1 1 —
Florida§ 16 15 57 907 1,059 — 0 2 8 2 — 0 1 3 1
Georgia N 0 0 N N — 0 1 4 4 — 0 3 8 —
Maryland§ N 0 0 N N — 0 3 16 — — 0 2 7 1
North Carolina N 0 0 N N — 0 0 — — — 0 0 — —
South Carolina§ — 0 35 75 113 — 0 1 1 3 — 0 0 — —
Virginia§ 7 11 34 478 678 — 0 1 2 5 — 0 1 1 —
West Virginia 8 8 26 410 465 — 0 0 — — — 0 0 — —
E.S. Central 7 5 22 268 514 — 0 1 8 36 — 0 3 10 27
Alabama§ 7 5 22 261 509 — 0 1 1 — — 0 1 2 —
Kentucky N 0 0 N N — 0 1 2 3 — 0 1 1 —
Mississippi — 0 2 7 5 — 0 1 3 29 — 0 2 5 22
Tennessee§ N 0 0 N N — 0 1 2 4 — 0 2 2 5
W.S. Central 28 46 285 2,431 4,511 — 0 15 97 117 — 0 3 17 35
Arkansas§ — 2 32 129 458 — 0 3 6 6 — 0 1 1 —
Louisiana — 1 5 40 124 — 0 3 14 10 — 0 1 6 11
Oklahoma N 0 0 N N — 0 0 — 8 — 0 0 — 2
Texas§ 28 41 272 2,262 3,929 — 0 15 77 93 — 0 2 10 22
Mountain 8 20 36 903 1,251 — 0 18 148 77 — 0 15 128 123
Arizona — 0 0 — — — 0 13 100 12 — 0 9 59 8
Colorado§ 8 8 18 369 484 — 0 5 26 36 — 0 11 55 67
Idaho§ N 0 0 N N — 0 0 — 9 — 0 1 3 29
Montana§ — 3 17 177 153 — 0 0 — 2 — 0 0 — 3
Nevada§ N 0 0 N N — 0 0 — 7 — 0 1 2 5
New Mexico§ — 2 8 91 112 — 0 5 19 6 — 0 2 4 2
Utah — 5 17 252 502 — 0 1 1 1 — 0 1 1 1
Wyoming§ — 0 3 14 — — 0 1 2 4 — 0 1 4 8
Pacific — 1 5 49 93 — 0 7 61 94 — 0 5 37 67
Alaska — 0 5 37 55 — 0 0 — — — 0 0 — —
California — 0 0 — — — 0 7 61 67 — 0 5 36 45
Hawaii — 0 2 12 38 — 0 0 — — — 0 0 — —
Oregon N 0 0 N N — 0 0 — 1 — 0 0 — 10
Washington N 0 0 N N — 0 0 — 26 — 0 1 1 12
Territories
American Samoa N 0 0 N N — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 2 15 28 — 0 0 — — — 0 0 — —
Puerto Rico — 9 30 501 485 — 0 0 — — — 0 0 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Case counts for reporting year 2010 are provisional and subject to change.  For further information on interpretation of these data, see http://www.cdc.gov/ncphi/disss/nndss/phs/files/
ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf.  Data for HIV/AIDS, AIDS and TB, when available, are displayed in Table IV, which appears quarterly.
† Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for California 
serogroup, eastern equine, Powassan, St. Louis, and western equine diseases are available in Table I.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
¶ Not reportable in all states. Data from states where the condition is not reportable are excluded from this table, except starting in 2007 for the domestic arboviral diseases and influenza-
associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/ncphi/disss/nndss/phs/infdis.htm.
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TABLE III. Deaths in 122 U.S. cities,* week ending November 20, 2010 (46th week)
Reporting area
All causes, by age (years)
P&I† 
Total Reporting area




Ages ≥65 45–64 25–44 1–24 <1
All  
Ages ≥65 45–64 25–44 1–24 <1
New England 577 394 120 32 12 19 46 S. Atlantic 1,129 706 296 87 24 14 69
Boston, MA 142 91 32 11 5 3 14 Atlanta, GA 135 78 35 12 6 2 7
Bridgeport, CT 27 23 4 — — — 3 Baltimore, MD 133 74 42 6 5 6 12
Cambridge, MA 22 15 5 1 — 1 1 Charlotte, NC 128 79 35 9 4 1 7
Fall River, MA 21 16 4 — 1 — 2 Jacksonville, FL 158 93 48 13 2 2 9
Hartford, CT 43 31 7 4 1 — 4 Miami, FL 34 23 9 2 — — 1
Lowell, MA 19 16 3 — — — 3 Norfolk, VA 39 27 10 1 — 1 1
Lynn, MA 6 5 1 — — — — Richmond, VA 59 38 14 7 — — 3
New Bedford, MA 35 27 6 2 — — — Savannah, GA 48 37 8 1 — 2 3
New Haven, CT 42 30 5 2 2 3 5 St. Petersburg, FL 53 37 8 8 — — 4
Providence, RI 72 53 15 — 1 3 3 Tampa, FL 205 134 51 17 3 — 13
Somerville, MA 3 1 2 — — — — Washington, D.C. 124 80 31 9 4 — 9
Springfield, MA 49 26 14 4 1 4 1 Wilmington, DE 13 6 5 2 — — —
Waterbury, CT 33 19 9 4 — 1 2 E.S. Central 864 594 196 37 18 19 60
Worcester, MA 63 41 13 4 1 4 8 Birmingham, AL 164 103 44 5 6 6 8
Mid. Atlantic 1,891 1,330 406 104 31 20 96 Chattanooga, TN 75 56 16 2 1 — 3
Albany, NY 45 34 9 1 1 — 1 Knoxville, TN 107 73 21 7 3 3 7
Allentown, PA 28 21 4 2 1 — — Lexington, KY 64 38 22 1 2 1 5
Buffalo, NY 82 59 17 5 — 1 6 Memphis, TN 164 114 38 9 2 1 17
Camden, NJ 20 15 2 2 1 — 2 Mobile, AL 86 63 17 6 — — 2
Elizabeth, NJ 19 9 8 2 — — 1 Montgomery, AL 32 25 6 1 — — 7
Erie, PA 47 32 11 4 — — 3 Nashville, TN 172 122 32 6 4 8 11
Jersey City, NJ 24 14 7 3 — — 2 W.S. Central 1,423 935 349 85 24 30 90
New York City, NY 1,037 737 223 49 17 11 52 Austin, TX 113 82 26 3 2 — 4
Newark, NJ 29 5 4 15 4 1 2 Baton Rouge, LA U U U U U U U
Paterson, NJ 15 7 6 2 — — 1 Corpus Christi, TX 59 38 16 3 1 1 8
Philadelphia, PA 200 126 57 8 4 5 8 Dallas, TX 189 118 50 8 3 10 15
Pittsburgh, PA§ 33 25 5 3 — — 1 El Paso, TX 101 70 22 8 1 — 2
Reading, PA 36 30 4 2 — — 4 Fort Worth, TX U U U U U U U
Rochester, NY 89 67 18 1 1 2 6 Houston, TX 438 272 115 34 7 10 26
Schenectady, NY 25 22 2 1 — — 1 Little Rock, AR 48 27 17 2 1 1 —
Scranton, PA 28 19 8 1 — — 2 New Orleans, LA U U U U U U U
Syracuse, NY 73 62 9 2 — — 3 San Antonio, TX 247 178 44 13 7 5 25
Trenton, NJ 27 19 6 1 1 — — Shreveport, LA 54 40 9 4 — 1 1
Utica, NY 15 13 1 — 1 — — Tulsa, OK 174 110 50 10 2 2 9
Yonkers, NY 19 14 5 — — — 1 Mountain 1,091 718 261 63 25 20 66
E.N. Central 2,111 1,414 486 128 37 46 130 Albuquerque, NM 115 77 23 9 5 1 10
Akron, OH 39 29 6 2 1 1 6 Boise, ID 59 45 13 1 — — 3
Canton, OH 46 31 11 4 — — 1 Colorado Springs, CO 58 42 12 3 — 1 3
Chicago, IL 222 139 71 9 3 — 19 Denver, CO 89 53 25 5 2 4 7
Cincinnati, OH 106 54 24 13 6 9 3 Las Vegas, NV 259 174 60 12 7 6 10
Cleveland, OH 263 186 59 9 — 9 13 Ogden, UT 33 24 6 2 — 1 1
Columbus, OH 237 156 56 19 2 4 10 Phoenix, AZ 194 116 52 14 6 4 10
Dayton, OH 138 99 29 7 1 2 7 Pueblo, CO 34 23 10 — 1 — —
Detroit, MI 158 88 56 8 4 2 7 Salt Lake City, UT 140 92 33 10 3 2 11
Evansville, IN 45 32 11 2 — — 6 Tucson, AZ 110 72 27 7 1 1 11
Fort Wayne, IN 82 55 18 5 2 2 2 Pacific 1,604 1,123 352 83 27 19 129
Gary, IN 23 12 4 7 — — — Berkeley, CA 11 11 — — — — 1
Grand Rapids, MI 63 49 8 2 3 1 4 Fresno, CA 129 83 32 10 3 1 5
Indianapolis, IN 193 127 41 16 3 6 20 Glendale, CA 33 30 2 1 — — 7
Lansing, MI 41 30 7 2 2 — 3 Honolulu, HI 63 50 10 2 1 — 11
Milwaukee, WI 95 63 23 7 2 — 6 Long Beach, CA 60 39 16 5 — — 5
Peoria, IL 51 36 6 6 1 2 4 Los Angeles, CA 242 159 60 12 8 3 24
Rockford, IL 56 41 8 1 4 2 5 Pasadena, CA 23 14 7 1 — 1 2
South Bend, IN 65 47 11 5 — 2 4 Portland, OR 104 70 23 6 3 2 10
Toledo, OH 126 88 29 3 3 3 4 Sacramento, CA 225 155 53 8 6 3 19
Youngstown, OH 62 52 8 1 — 1 6 San Diego, CA 38 30 5 1 1 1 2
W.N. Central 657 419 156 40 18 23 45 San Francisco, CA 101 63 31 4 — 3 8
Des Moines, IA 37 20 11 2 1 3 1 San Jose, CA 205 154 37 12 1 1 16
Duluth, MN 40 29 8 1 1 1 3 Santa Cruz, CA 31 23 5 2 1 — 2
Kansas City, KS U U U U U U U Seattle, WA 144 100 31 9 1 3 5
Kansas City, MO 96 65 23 3 3 2 10 Spokane, WA 70 51 11 5 2 1 4
Lincoln, NE 55 49 5 1 — — 5 Tacoma, WA 125 91 29 5 — — 8
Minneapolis, MN 71 44 21 4 1 1 6 Total¶ 11,347 7,633 2,622 659 216 210 731
Omaha, NE 94 64 19 6 3 2 6
St. Louis, MO 205 112 58 16 8 10 12
St. Paul, MN 59 36 11 7 1 4 2
Wichita, KS U U U U U U U
U: Unavailable.   —: No reported cases.   
* Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of >100,000. A death is reported by the place of its occurrence and 
by the week that the death certificate was filed. Fetal deaths are not included.
† Pneumonia and influenza.
§ Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.
¶ Total includes unknown ages.
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